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Abstract 21 
Metformin is a first-line drug for the treatment of individuals with type 2 diabetes, yet its 22 
precise mechanism of action remains unclear. Metformin exerts its anti-hyperglycemic 23 
action primarily through lowering of hepatic glucose production (HGP). This suppression 24 
is thought to be mediated through inhibition of mitochondrial respiratory complex I, and 25 
thus elevation of 5’-adenosine monophosphate (AMP) levels and the activation of AMP-26 
activated protein kinase (AMPK), though this proposition has been challenged given 27 
results in mice lacking hepatic AMPK. Here, we report that the AMP-inhibited enzyme 28 
fructose-1,6-bisphosphatase-1 (FBP1, EC 3.1.3.11), a rate-controlling enzyme in 29 
gluconeogenesis, functions as a major contributor to the therapeutic action of 30 
metformin. We identified a point mutation in FBP1 that renders it insensitive to AMP 31 
while sparing regulation by fructose-2,6-bisphosphate (F-2,6-P2) and knockin (KI) of 32 
this mutant into mice significantly reduces their response to metformin treatment. We 33 
observe this during a metformin tolerance test and in a metformin-euglycemic clamp 34 
that we have developed. The anti-hyperglycemic effect of metformin in high fat diet-fed 35 
diabetic FBP1 KI mice was also significantly blunted compared to wild-type controls. 36 
Collectively, we show a new mechanism of action of metformin, while providing further 37 
evidence that molecular targeting of FBP1 can have anti-hyperglycemic effects.  38 
Diabetes is characterized by impaired glucose homeostasis partly due to abnormally elevated hepatic 39 
glucose production (HGP). The biguanide drug metformin (N,N-dimethylbiguanide) works principally 40 
through inhibition of HGP, although enhanced glucose disposal has also been reported in some 41 
studies1. It is widely accepted that metformin inhibits mitochondrial respiration through complex I2-4, 42 
reducing hepatocellular energy charge. A previous study examined if metformin-mediated AMP-43 
activated protein kinase (AMPK) activation is responsible for its therapeutic effects and the reported 44 
data supporting a mechanism involving AMPK-dependent inhibition of HGP and lipogenesis5 albeit 45 
using an inhibitor of questionable selectivity6. Indeed a recent study has demonstrated that inhibitory 46 
phosphorylation of acetyl-CoA carboxylase (ACC) by AMPK plays an important role in metformin-47 
induced improvements in insulin action by maintaining hepatic lipid homeostasis7. However, the 48 
significance of AMPK in metformin action on HGP has been challenged in experiments using mice 49 
lacking hepatic AMPK8. Recent studies report that metformin inhibits HGP through hepatic AMPK-50 
independent mechanisms, either by attenuating the ability of glucagon to increase 3’,5’-cyclic 51 
adenosine monophosphate (cAMP) levels and promote HGP9 or direct inhibition of mitochondrial 52 
glycerol-3-phosphate dehydrogenase and subsequent increase in cytosolic free [NADH]:[NAD+] 53 
leading to impaired utilization of lactate for gluconeogenesis10. These findings suggest that the 54 
underlying mechanisms responsible for the HGP- and glucose-lowering effects of metformin in 55 
diabetes may not be explained by any single target or pathway. Interestingly, a widely-used 56 
pharmacological AMPK activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), 57 
an AMP mimetic, profoundly suppressed glucose output in hepatocytes lacking AMPK8,11, indicating 58 
AMP per se but not AMPK plays a vital role in suppressing HGP. Similarly, a tight correlation 59 
between the magnitude of increase in [AMP]:[ATP] and inhibition of glucose output in hepatocytes 60 
has been noted8.  61 
Given that the anabolic process of gluconeogenesis is energetically costly, hepatocytes must 62 
balance this energy demand with production thereby maintaining energy homeostasis. Hepatocytes are 63 
equipped with a mechanism to control the rate of hepatic gluconeogenesis in response to energy status 64 
and fructose bisphosphatase 1 (FBP1) has long been recognized as a key component12. FBP1 catalyzes 65 
the irreversible hydrolysis of fructose-1,6-bisphosphate (F-1,6-P2) to fructose-6-phosphate (F6P) and 66 
inorganic phosphate (Pi) in the presence of divalent cations. FBP1 is a key rate-controlling enzyme in 67 
the gluconeogenic pathway and individuals with FBP1 deficiency present with hypoglycemia and 68 
metabolic acidosis due to impaired gluconeogenesis13. FBP1 activity is regulated synergistically by the 69 
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allosteric inhibitors AMP and F-2,6-P2. AMP inhibits noncompetitively by binding to a unique 70 
allosteric site whereas F-2,6-P2 binds to the active site in competition with F-1,6-P2. While levels of F-71 
2,6-P2 are largely under hormonal control, AMP concentration is a function of the energy status of the 72 
tissue and contributes to autoregulation of gluconeogenesis. We hypothesized that acute inhibition of 73 
gluconeogenesis by metformin is due to inhibition of FBP1, secondary to increases in the AMP 74 
concentration through reducing hepatocellular energy charge.  75 
 76 
Results 77 
 78 
Identification of an AMP insensitive FBP1 mutant  79 
Demonstrating the importance of allosteric regulation of a rate-controlling enzyme in 80 
metabolic flux control in vivo is difficult partly due to the lack of an established experimental strategy. 81 
The only definitive approach is to generate a knockin (KI) animal model that specifically renders the 82 
target enzyme insensitive to the ligand of interest, while leaving all other modes of regulation intact14. 83 
Such a mutant cannot be designed from basic principles and can only be chosen on the basis of 84 
available or predicted structure combined with detailed in vitro enzyme kinetic analysis. Before 85 
designing such a point mutant of FBP1, we first established that metformin does not have a direct 86 
inhibitory effect on FBP1 up to 10 mM (Supplementary Fig. 1a). Neither does it appear to inhibit the 87 
reported target AMP deaminase 1 (AMPD1)15 (Supplementary Fig. 1a).  88 
Next, to identify an AMP-resistant FBP1 mutant, we performed structure-guided mutagenesis 89 
based on the reported structure of the human FBP1-AMP complex16 (PDBID 1FTA) (Fig. 1a) and 90 
evolutionary conservation of key AMP-contacting residues (Supplementary Fig. 1b). Several point 91 
mutants designed to disrupt AMP binding to mouse FBP1 were prepared using an Fbp1-null E.coli 92 
strain. Native FBP1 from mouse liver was purified and used as a reference material to validate 93 
recombinant mouse 6HIS-FBP1. We obtained high-purity recombinant and native FBP1 as judged by 94 
Coomassie-stained SDS-PAGE gels (Fig. 1b). IC50 values for AMP were comparable between 95 
recombinant wild-type (WT) and native mouse liver FBP1 at ~14 and ~20 μM, respectively (Fig. 1c). 96 
Among the mutants tested, we found that G27P and Y114F showed markedly higher IC50 values for 97 
AMP (4420 and 13300 μM, respectively) and were essentially unaffected by up to 1 mM AMP, a 98 
concentration expected to greatly exceed in vivo limits (Fig. 1c). We subjected G27P and Y114F to 99 
further analysis using untagged preparations and ultimately rejected further exploration of Y114F due 100 
to an increased IC50 for F-2,6-P2 (data not shown), while we determined the detailed kinetic properties 101 
of G27P (Supplementary Table 1). Core properties including specific activity and the apparent 102 
affinity/Hill coefficient for ligands (F-1,6-P2, Mg2+ and F-2,6-P2) were essentially identical between 103 
WT and G27P mutant. In contrast, IC50 for G27P compared to WT protein was drastically higher for 104 
AMP and related compounds, including the active form of AICAR, 5’-AICAR monophosphate 105 
(ZMP), and two nucleotide-mimetic commercial FBPase inhibitors.  106 
Interestingly, inhibition by 5-inosine monophosphate (IMP) was unaffected. While not a 107 
physiologically relevant ligand for FBP1, this highlights that the substitution has not disrupted the 108 
function of the allosteric pocket, but merely reduced the affinity for AMP beyond the physiological 109 
range. Indeed, titration with the fluorescent AMP analogue, TNP-AMP demonstrated a significant 110 
reduction in binding affinity (Supplementary Table 1), which was further confirmed by the inability 111 
of G27P FBP1 to bind AMP immobilized on a solid support (Supplementary Fig. 1c). Finally, we 112 
assessed thermal stability as an indicator of the stability of the folded state of the mutant 113 
(Supplementary Fig. 1d). Melting temperature (Tm) was essentially unaffected by the G27P 114 
substitution (69.2 ± 0.2 ºC vs. 68.6 ± 0.2 ºC). Interestingly, saturating AMP concentration did not shift 115 
Tm for WT but substantially reduced resting fluorescence at ambient temperature revealing a clear 116 
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biphasic transition from the more closed tense (T) state upon heating. As expected, this was not 117 
observed for G27P but the stabilizing effect of F-1,6-P2 was conserved. 118 
 119 
Generation and characterization of an AMP insensitive FBP1 G27P KI mouse model 120 
To establish if AMP-mediated inhibition of FBP1 activity contributes to the anti-121 
hyperglycemic action of metformin in vivo, we generated an FBP1 KI mouse model in which the 122 
codon for glycine 27 of Fbp1 was modified to encode proline (Fig. 1d). FBP1 is predominantly 123 
expressed in liver and kidney and to a much lesser extent in testes and small intestine (Supplementary 124 
Fig. 2a). Although expression of FBP1 in islets has been reported17, it was undetectable in our hands 125 
using a highly specific antibody (Supplementary Fig. 2a). We confirmed that expression and activity 126 
of FBP1 were comparable between homozygous FBP1G27P/G27P KI and control WT mice in liver and 127 
kidney, although FBP1 expression in KI mice was modestly higher in small intestine and lower in 128 
testes compared to WT (Fig. 1e and Supplementary Fig. 2b,c). Assayed in crude liver extracts, FBP1 129 
G27P exhibited > 400-fold higher IC50 for AMP compared to WT FBP1 (Fig. 1e), which is far beyond 130 
the physiological range of cellular AMP concentrations18.  131 
FBP1G27P/G27P mice were born at the expected Mendelian frequency and displayed similar body 132 
weight and growth curves (data not shown), food intake and respiratory exchange ratio, as well as 133 
locomotor activity compared to WT mice (Supplementary Fig. 3a-f). Compared to WT, FBP1 KI 134 
mice exhibited similar blood glucose, plasma insulin, glucagon and leptin levels, as well as hepatic 135 
glycogen content under fasted and refed (4 h ad libitum following overnight fast) conditions (Fig. 2a-136 
e). KI mice also displayed normal blood glucose tolerance (Fig. 2f) and gluconeogenic capacity 137 
assessed by pyruvate tolerance test (Fig. 2g). Consistent with these observations, immunoblot analysis 138 
revealed comparable expression of major metabolic proteins involved in hepatic glucose metabolism 139 
(e.g. GLUT2, glucokinase (GCK) and its regulator protein GCKR, hexokinase 1 (HXK1), 140 
phosphofructokinase (PFKL), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB1), 141 
FBP1 and glucose-6-phosphate dehydrogenase (G6PD)), glycogen metabolism (e.g. glycogen synthase 142 
(GYS2) and glycogen phosphorylase (PYGL)) and gluconeogenesis (e.g. catalytic and transporter 143 
subunit of glucose-6 phosphatase (G6PC/T), cytosolic/mitochondrial isoforms of 144 
phosphoenolpyruvate carboxykinase (PEPCK-C/M), pyruvate carboxylase (PC), pyruvate kinase 145 
(PKLR)) as well as the major metformin transporter organic cation transporter 1 (OCT1) between WT 146 
and KI under fasted and refed conditions (Fig. 2h and Supplementary Fig. 4). Moreover, the activity 147 
of the major gluconeogenic/glycolytic enzymes were similar between WT and KI under both fasted 148 
and refed conditions (Supplementary Fig. 5a-i). At transcript level, mRNA expression of genes 149 
involved in gluconeogenesis (Pck1, Pparg1c, Foxo1a) and lipogenesis (Fasn) were similar between 150 
WT and KI mice (Supplementary Fig. 5j-m). Conversely, G6pc mRNA level was significantly lower 151 
in KI mice under both fasted and refed conditions (Supplementary Fig. 5n), although this did not 152 
translate into a difference at protein level (Fig. 2h and Supplementary Fig. 4b) or activity 153 
(Supplementary Fig. 5b). Similarly, Gck mRNA was higher in refed KI mice (Supplementary Fig. 154 
5o); however, again, protein levels and enzyme activity were unchanged (Supplementary Fig. 4d and 155 
Supplementary Fig. 5a). Phosphorylation states of hormone- and/or nutrient-regulated proteins 156 
showed the anticipated changes in response to refeeding such as increased phosphorylation of p70S6K 157 
and S6, downstream components of mTOR, and decreased phosphorylation of GYS2 and PYGL, as 158 
well as PFKFB1, the enzyme that synthesizes F-2,6-P2 and a major substrate of cAMP-dependent 159 
protein kinase (Fig. 2h and Supplementary Fig. 4). Hepatic lactate and pyruvate are the major three 160 
carbon precursors for gluconeogenesis and their levels were unchanged between WT and KI mice 161 
under both fasted and refed conditions (Supplementary Table 2). Likewise, hepatic glucose and G6P 162 
concentrations were similar between WT and KI. Furthermore, there was no difference in the levels of 163 
F6P and F-1,6-P2, the substrate and product of FBP1, respectively (Supplementary Table 2). The loss 164 
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of regulation by AMP of FBP1 does not have an apparent impact on gluconeogenic flux under normal 165 
conditions. The mutant does remain sensitive to hormonal regulation by F-2,6-P2, whose levels were 166 
also unchanged between WT and KI. Hepatic adenine nucleotide levels and energy charge were 167 
similar in fasted and refed conditions and comparable between WT and KI mice (Supplementary 168 
Table 3). Taken together, these results demonstrated that FBP1 KI mice possess normal hepatic 169 
energy and metabolic homeostasis, as well as whole body glucose homeostasis. 170 
 171 
FBP1 G27P KI mice are resistant to the hypoglycemic action of AMP mimetic compounds 172 
Prior to testing the effect of metformin, we wanted to confirm if FBP1G27P/G27P KI mice are 173 
resistant to AMP-mediated blood glucose-lowering in vivo. For this purpose, we initially used the 174 
AMP mimetic FBPase inhibitor MB06322 (ref. 19), the pro-drug of MB05032 (Fig. 3a and 175 
Supplementary Table 1). We observed that recombinant mouse FBP1 was ~2-fold less sensitive to 176 
MB05032 compared to rat FBP1 in vitro, while sensitivity to AMP was comparable between the two 177 
species (Fig. 3b). As all available pre-clinical data was only performed in rats, we took this species 178 
difference in drug response into account and 75 mg.kg-1 of MB06322 was administered (i.p.) to WT 179 
and KI mice. In WT animals MB06322 treatment resulted in a robust and sustained decrease (~40 % at 180 
2-3 h post injection) in blood glucose levels (Fig. 3c), which was accompanied by an increase in blood 181 
lactate levels (Fig. 3d). In contrast, even though plasma concentration of the drug was comparable 182 
between genotypes (Fig. 3e), MB06322 had no significant effect on both blood glucose and lactate 183 
concentration in KI mice (Fig. 3f, g). We next sought to determine if the well-documented 184 
hypoglycemic effect of AICAR20, which is converted intracellularly to the AMP-mimetic ZMP (Fig. 185 
4a), is mediated through ZMP-dependent inhibition of FBP1 in vivo. Administration of AICAR (250 186 
mg.kg-1, i.p.) resulted in a profound (up to ~60 %) decrease in blood glucose levels in WT (Fig. 4b), 187 
but not in KI (Fig. 4c) mice, while plasma concentration of AICAR was similar between the two 188 
genotypes (Fig. 4d). Consistent with the results observed with MB06322, AICAR induced a marked 189 
increase in blood lactate levels in WT (Fig. 4e), but only modestly in KI (Fig. 4f) mice. Plasma 190 
glucagon levels were increased only in AICAR-treated WT (Fig. 4g), but not in KI (Fig. 4h) mice, 191 
most likely to counteract the rapid induction of hypoglycemia (Fig. 4b). There was no significant 192 
change in plasma insulin levels (Fig. 4i,j). As anticipated, AICAR robustly stimulated phosphorylation 193 
of liver AMPK and its bona fide substrate ACC in both WT and KI mice (Fig. 4k,l). This was 194 
accompanied by a profound increase in liver ZMP and ZTP concentrations in both genotypes 195 
(Supplementary Table 4). As previously reported in both intact animals11,20 and isolated 196 
hepatocytes12,21 AICAR administration in WT mice resulted in a substantial decrease in the total 197 
adenine nucleotide pool (Supplementary Table 4). The conversion of AICAR to ZMP by adenosine 198 
kinase consumes ATP and acts as a trap for phosphate, similar to the metabolic consequences of a 199 
large fructose bolus. This effect is further enhanced by significant substrate cycling between AICAR 200 
and ZMP due to dephosphorylation by 5’-nucleotidase22. This leads to depletion of Pi resulting in de-201 
inhibition of AMP deaminase and the loss of adenine nucleotides. However, this mechanism cannot be 202 
fully responsible as AICAR had minimal effect on adenine nucleotides in KI mice despite similar 203 
accumulation of ZMP (Supplementary Table 4). Furthermore, AICAR was previously observed to 204 
have no significant effect on ATP levels in fed mice20. The common factor here is likely the absence 205 
of an acute glucose-lowering effect and inhibition of a high gluconeogenic flux which leads to the 206 
accumulation of additional phosphorylated species (e.g. F-1,6-P2 and the triose phosphates) as 207 
additional sinks for Pi (data not shown). Interestingly, AICAR treatment lead to a similar increase in 208 
hepatic NAD+ in both WT and KI mice (Supplementary Table 4), which is likely due to AMPK-209 
dependent inhibition of fatty acid synthesis and subsequent increase in β-oxidation. 210 
In skeletal muscle, AICAR failed to increase AMPKα T172 phosphorylation and activity in 211 
both genotypes (Supplementary Fig. 6a-c), although it enhanced phosphorylation of ACC and TBC1 212 
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domain family member 1 (TBC1D1) most likely via ZMP-dependent allosteric activation of AMPK 213 
(Supplementary Fig. 6d, e). Notably, AICAR was unable to stimulate phosphorylation of RAPTOR 214 
which is a marker of more robust AMPK activation23 (Supplementary Fig. 6f). Indeed ZMP 215 
concentration and [ZMP]:[ATP] ratio in skeletal muscle were > 50-fold and > 150-fold less, 216 
respectively, compared to that detected in the liver following AICAR treatment, a consequence of the 217 
significant first-pass metabolism of AICAR and low plasma concentration (Supplementary Table 4 218 
and Supplementary Fig. 6g). Thus, it is presumed that the magnitude of AMPK activation following 219 
AICAR treatment in skeletal muscle was below the threshold to cause blood glucose-lowering in KI 220 
mice through promoting glucose uptake in this tissue. Collectively, using two AMP mimetic drugs we 221 
have confirmed that the FBP1 KI model is suitable to investigate the effect of an AMP-elevating agent 222 
(i.e. metformin) on blood glucose in vivo. 223 
 224 
FBP1 G27P KI mice are metformin intolerant  225 
To determine if FBP1 KI mice exhibited altered responses to an acute dose of metformin, we 226 
performed a metformin tolerance test. Since metformin affects intestinal glucose absorption24, we 227 
intraperitoneally injected glucose (2 g.kg-1) following an oral administration of 250 mg.kg-1 metformin 228 
(Supplementary Fig. 7a), a commonly used dose in rodents to elicit an acute glucose-lowering 229 
effect7-9,25. Prior administration of metformin promoted significantly faster disappearance of blood 230 
glucose compared to vehicle-treated control in FBP1 WT mice (Fig. 5a). In contrast, metformin’s 231 
glucose-lowering effect was significantly lower in KI mice (Fig. 5b) even though plasma and liver 232 
metformin levels (~125-150 μM and ~0.7 μmol.g-1 respectively) were comparable between genotypes 233 
(Fig. 5c). Metformin caused a comparable increase in hepatic [AMP]:[ATP] (~2-fold) and decreased 234 
energy charge (~10 %) in both genotypes (Supplementary Table 5). This change in energy status was 235 
associated with a robust increase in phosphorylation of liver AMPK and ACC (Fig. 5d,e).  236 
To further investigate whether FBP1 KI mice were resistant to the glucose-lowering effect of 237 
metformin in vivo, we developed and optimized a “metformin-euglycemic clamp” protocol in the 238 
conscious, unrestrained mouse (Supplementary Fig. 7b). A similar technique has been used 239 
previously to assess the effect of metformin on HGP in mice26. Two different doses of metformin 240 
(1.875 mg.kg-1.min-1 and 3.75 mg.kg-1.min-1) were tested. Metformin was infused intravenously at a 241 
constant rate, while the glucose infusion rate (GIR) was adjusted to maintain euglycemia (Fig. 5f). We 242 
observed that the lower dose (1.875 mg.kg-1.min-1) failed to increase GIR significantly from baseline 243 
in WT (and also KI) mice under euglycemic condition (Supplementary Fig. 7c,d), even though 244 
metformin had reached ~170 μM and ~0.8 μmol.g-1 in plasma and liver, respectively (Supplementary 245 
Fig. 7e). These concentrations were comparable to those observed following an acute oral 246 
administration of 250 mg.kg-1 (Fig. 5c). This is likely due to differences in the route of administration. 247 
The first-pass of metformin from the gastrointestinal tract, via the portal vein and liver, into systemic 248 
circulation is crucial for the glucose-lowering effect. Firstly, administration of metformin via the 249 
portal-hepatic pathway produces more profound glucose-lowering than direct systemic infusion27. 250 
Secondly, it has been proposed that there is also a direct effect of metformin on the gut itself. For 251 
example, it has been recently suggested that metformin reduces HGP through a gut-brain-liver 252 
neuronal network via activation of AMPK in the duodenum resulting in release of GLP-128. Another 253 
study has shown that metformin reshapes the gut microbiota through interacting with different 254 
bacteria, possibly via metal homeostasis29.  255 
Infusion of a higher dose of metformin (3.75 mg.kg-1.min-1) resulted in a substantial increase 256 
in GIR leading to steady state by the end of the 120 min clamp in WT mice (Fig. 5g). In contrast, KI 257 
mice displayed only a modest increase in GIR (Fig. 5g), even though plasma and liver/muscle 258 
metformin, as well as plasma insulin concentrations were similar between genotypes (Fig. 5h and 259 
Supplementary Fig. 7f,g). Combining the metformin-euglycemic clamp with administration of 2H 260 
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stable isotope tracers enabled the quantification of endogenous glucose production (EndoRa) including 261 
the relative contribution of glycogenolysis and gluconeogenesis. EndoRa was significantly suppressed 262 
(~20 %) in WT during the clamp (Fig. 5i). This was due to reduction of both gluconeogenesis and 263 
glycogenolysis (Fig. 5j,k). In contrast, metformin-induced suppression of EndoRa, gluconeogenesis 264 
and glycogenolysis, was ablated in FBP1 KI mice (Fig. 5i-k). Overall, the clamp study revealed that 265 
KI mice were largely insensitive to the glucose-lowering effect of metformin due to ablation of 266 
metformin-induced suppression of HGP. However, it should be noted that due to the systemic route of 267 
delivery (as mentioned above), much higher and supra-pharmacological doses were needed to elicit a 268 
robust glucose-lowering effect resulting in artificially higher glucose disposal rate (~40-50 % increase 269 
in both WT and KI) than is seen at therapeutic doses (Fig. 5l). It has been shown that metformin can 270 
stimulate glucose uptake in isolated rat skeletal muscle at supra-pharmacological doses (but not at 271 
clinical doses due to the absence of OCT130) by activating AMPK5, which could sensitize insulin 272 
action and further promote glucose uptake in muscle31. In support of this premise, metformin 273 
concentration in skeletal muscle was increased 2-fold when infused at the higher rate (3.75 mg.kg-274 
1.min-1) compared to the lower rate (1.875 mg.kg-1.min-1) (Supplementary Fig. 7g). The molecular 275 
basis underlying reduced glycogenolysis in WT mice during the clamp is unknown, as we observed no 276 
significant difference in the levels of phosphorylation/activity of glycogen synthase (GS) and glycogen 277 
phosphorylase (GPa), as well as hepatic glycogen content between genotypes at the end of the clamp 278 
(Supplementary Fig. 7h-m). We monitored tissue distribution and pharmacokinetics of metformin 279 
via systemic route and performed positron emission tomography (PET) analysis following an acute 280 
intravenous infusion of [11C]-metformin. We found that the kinetics and total metformin uptake in 281 
liver was comparable between WT and KI mice (Supplementary Fig. 8) consistent with the snapshot 282 
measurements of hepatic metformin concentration as shown in Fig. 5c and Supplementary Fig. 7e. In 283 
addition, PET analysis highlighted a rapid and marked accumulation of metformin in the bladder, 284 
corroborating the need for a much higher dose to achieve a glucose-lowering effect via systemic route 285 
than gastrointestinal route. 286 
 287 
FBP1 G27P KI mice are resistant to the acute hypoglycemic action of metformin in an obesity-288 
induced model of diabetes  289 
We next assessed if FBP1 KI mice were resistant to the glucose-lowering effect of metformin 290 
under hyperglycemic/diabetic condition. WT and KI mice were fed with high-fat diet (HFD) for 10 291 
weeks and both genotypes had similar profiles of weight gain and food intake over the period of 292 
dietary intervention (Fig. 6a,b). HFD-fed WT and KI mice showed hallmark features of type 2 293 
diabetes, including glucose intolerance, hyperglycemia, hyperinsulinemia as well as 294 
hypertriglyceridemia (Fig. 6c-f). At the end of HFD intervention, we orally treated WT and KI mice 295 
with metformin (250 mg.kg-1) or vehicle (water) and monitored blood glucose levels two hours post 296 
treatment. We found that metformin, but not vehicle, produced a significant reduction of blood 297 
glucose levels in WT (~30-40 %), but the effect was significantly blunted in KI mice (P = 0.047, Fig. 298 
6g,h). We verified that hepatic metformin levels (Fig. 6i) and the magnitude of changes in 299 
[AMP]:[ATP], energy charge (Supplementary Table 6), as well as associated increases in AMPK 300 
phosphorylation (Fig. 6j) were comparable between genotypes. Inhibition of gluconeogenesis by 301 
metformin in WT mice could also be supported by a modest fall in hepatic glucose and G6P levels, 302 
which was blunted in KI animals. Similarly, inhibition of the step catalyzed by FBP1 was suggested 303 
by a decrease in F6P (P = 0.053) and a concomitant increase in F-1,6-P2, in livers from metformin-304 
treated mice (P = 0.091) that was lower in KI animals (Supplementary Table 7). However, given that 305 
there was a modest (~10 %), but significant effect for metformin to decrease blood glucose in KI mice 306 
(Fig. 6h), there must be additional mechanisms, independent of AMP-mediated FBP1 inhibition, to 307 
lower blood glucose. This is unsurprising given that metformin has multiple proposed primary and 308 
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secondary targets1, including mitochondrial complex I2-4 and glycerol-3-phosphate dehydrogenase10 in 309 
the liver, as well as duodenal AMPK28. While it has been proposed that one of the mechanisms of 310 
action of metformin involves a reduction in hepatic cAMP9 (a key mediator of glucagon signaling), 311 
there was no significant effect (Fig. 6k) and an actual increase in downstream phosphorylation of PKA 312 
substrates (i.e., pS33 PFKFB1 and pS133 cAMP response element–binding protein  (CREB)) 313 
(Supplementary Fig. 9a,b) under the conditions of our model system, (it has been reported that the 314 
reduction in cAMP is only apparent at substantially higher dose [i.e. 400 mg.kg-1]7), although we 315 
cannot rule out the possibility that we have missed the time point where cAMP-PKA signaling was 316 
suppressed following metformin treatment. 317 
 318 
Discussion 319 
Metformin has been in use for more than 50 years as an antihyperglycemic agent for the 320 
treatment of diabetes. Despite the clinical success of metformin, there is no clear consensus as to its 321 
mode of action and multiple, seemingly contradictory mechanisms, have been proposed. However, a 322 
common narrative emerges when a clear distinction is drawn between acute vs. chronic effects of 323 
metformin that can be mediated by either direct or indirect effects on HGP by metabolic or genic 324 
means. We have focused specifically on the acute effect of metformin on HGP, where it is clear that 325 
AMPK is dispensable. Hepatic AMPK-null mice do not exhibit a defect in either steady state 326 
glycemia, glucose/pyruvate tolerance or the acute glucose-lowering effect of metformin8. Furthermore, 327 
treatment of cultured hepatocytes8 or i.v. infusion of the specific AMPK activator A769662 has no 328 
effect on glucose production10. While hepatic LKB1-null mice present with severe hyperglycemia and 329 
hyperlipidemia due to upregulation of CREB/peroxisome proliferator-activated receptor-gamma 330 
coactivator 1α (PGC1α) transcriptional targets (Pck1 and G6pc)32, recent work suggests that this is due 331 
to impaired activity of the AMPK-related kinase, salt-inducible kinase (SIK)33, and not AMPK. Much 332 
is often made of the short-term changes in Pck1 and G6pc mRNA in response to pharmacological 333 
activation of AMPK, but when protein levels are assessed they are invariably unaltered. Indeed, a poor 334 
correlation has been noted between the expression of gluconeogenic genes and HGP34. In short, 335 
although biguanides can clearly activate AMPK, it is neither sufficient nor necessary for acute 336 
inhibition of HGP.  337 
 Obesity-induced diabetes is a standard model in rodent studies and it is generally accepted that 338 
the associated hyperglycemia is a consequence of hepatic insulin resistance in fatty livers. It is well 339 
established that AMPK is a critical regulator of lipogenesis and chronic treatment of diabetic mice 340 
with metformin significantly improves glucose tolerance by reducing hepatic steatosis and improving 341 
insulin resistance. Of note, mice expressing non-phosphorylatable mutants of ACC1 and ACC2 342 
(ACC1/2 knockin), were resistant to the lipid and glucose-lowering effect of chronic metformin 343 
treatment. Significantly, the acute hypoglycemic effect of a single dose of metformin was unaffected7. 344 
The same mechanism likely underpins the glucose-lowering effect of chronic A769662 treatment in 345 
obese ob/ob mice where dramatic reductions in hepatic and plasma lipid were observed35. 346 
Consequently, AMPK plays a role in the chronic, indirect inhibition of HGP by alleviating hepatic 347 
insulin resistance. 348 
Plasma metformin concentration in humans is markedly variable, due in part to the complex 349 
pharmacokinetics of the drug and profound inter-subject variations in absorption and elimination36. It 350 
is difficult to quote a meaningful elimination half-life (t½) because the time course of plasma 351 
concentrations of metformin follows a multiphasic pattern, but values in the range from 1.7 to 4.5 352 
hours have been reported36. Plasma metformin concentration in patients treated with a normally 353 
prescribed dose of metformin (1 g, twice a day) has been reported within 0.4-32 μM range (plasma 354 
levels obtained 14 hours after last drug administration) in 159 type 2 well-regulated diabetic subjects 355 
under controlled conditions37. In contrast, plasma metformin levels between 0 and 113 mg/L (868 μM) 356 
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have been measured in random blood samples from diabetic subjects38. Both studies have provided 357 
useful information, as the former37 gives an estimate of nadir during multiple dosing, whereas the 358 
latter38 provides a valuable estimate of Cmax of metformin during clinical use. However, overall it has 359 
been to date a challenge to establish the therapeutic range of metformin concentrations in plasma.  360 
The current debate on metformin has turned towards the issue of the validity of the 361 
concentrations and doses used in rodent models. It has long been recognized that the effective 362 
hypoglycemic dose exhibits a marked species dependence and researchers rightly use doses that 363 
produce robust, reproducible effects. In this regard, it is difficult to compare studies that have not 364 
measured plasma and/or liver accumulation as the drug formulation, route of administration and 365 
degree of fasting will impact the pharmacokinetics. Species differences in OCT1 expression have also 366 
been identified; while both rodent and human liver express OCT1, its expression in human intestines 367 
appears much lower than in mice39. As metformin is administered orally, differences in intestinal 368 
OCT1 expression may affect portal vein levels of metformin and thereby hepatic uptake without 369 
detectable effects on metformin levels in peripheral veins. In addition, hepatic exposure to the drug 370 
depends not only on OCT1 but also multidrug and toxin extrusion (MATE) isoforms acting as influx 371 
and efflux transporters, respectively. Differential hepatic expression of MATE1 between humans and 372 
rodents has been reported40, which may also affect metformin kinetics. It has been observed that a 373 
glucose-lowering effect occurs in response to a single dose of 50 mg.kg-1 in rats10. However, it should 374 
be noted that metformin (50 mg.kg-1) was given intravenously, which led to plasma metformin 375 
concentration of ~74 μM 30 min after administration, while 100 mg.kg-1 and 250 mg.kg-1 doses 376 
increased plasma metformin concentration of 345 μM and 1300 μM, respectively10. Further, the study 377 
exploring the effect of metformin in ACC1/2 KI mice used a chronic dose of 50 mg.kg-1 (i.p.) for 12 378 
weeks, however, a dose of 200 mg.kg-1 was needed (50 mg.kg-1 had no effect) to observe a glucose-379 
lowering effect in single-dose experiments7. Taken together, the dose range 200-350 mg.kg-1 has 380 
consistently been used7-9,25 and indeed the dose used in our study is similar to the maximum daily 381 
human dose (2 g) when allometric scaling is applied (dose for 25 g mouse = 2000×(0.025/65)0.75 = 5.5 382 
mg = 220 mg.kg-1).  383 
With cultured hepatocytes it is typical to see claims of enhanced justification on the basis of 384 
using lower doses but for greatly increased periods of time (often 16-24 h). Given that the uptake of 385 
metformin in isolated hepatocytes is relatively slow2 (in contrast to the rapid uptake in human and 386 
rodent livers in vivo41,42) and potentially antagonized by competing OCT substrates in complex 387 
media43, intracellular accumulation is both time and concentration dependent such that higher drug 388 
concentrations will reach effective intracellular levels within more relevant time periods. The apparent 389 
discrepancy in reported efficacy of metformin on isolated hepatocytes is likely due to the wide range 390 
of culture conditions used with respect to media (complex vs. balanced salt solutions), carbon sources 391 
and hormones. Indeed, under commonly used conditions for glucose production assays where the sole 392 
carbon sources are typically lactate and pyruvate, metformin produces precipitous decreases in 393 
intracellular ATP concentration (~85 % reduction at 1 mM) that closely follow apparent changes in 394 
glucose production or gene expression8. Such extremes in adenylate energy charge are not observed in 395 
any physiological setting in vivo. Consequently, the lack of standardization in hepatocyte protocols 396 
and the ease with which extreme energy deprivation can be induced with metformin renders the many 397 
reported results difficult to consolidate. 398 
The final area of controversy concerns the role of changes in adenine nucleotides in metformin 399 
action. Several early studies reported activation of AMPK in the apparent absence of increases in 400 
AMP concentration44, which has been used to argue that metformin does not alter cellular energetics. 401 
However, experiments using AMP-resistant AMPKγ2 mutants have clarified that AMPK activation by 402 
metformin and essentially all xenobiotic compounds is mediated by increases in AMP concentration45. 403 
Technical errors in many contemporary studies have resulted in misleading values reported for hepatic 404 
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adenine nucleotides ([ATP]:[AMP] <<10, often approaching 1). Hepatic AMP concentration is a very 405 
sensitive indicator of stress and increases by ~10-fold within just 30 seconds of hypoxia18. 406 
Consequently, tissues must be freeze-clamped in-situ to enable accurate measurements and reveal 407 
subtle changes in energy status. Even then, AMPK can easily be activated by increases in free AMP 408 
concentrations that are below the limit of quantification. Consequently, AMPK is a sensitive reporter 409 
of subtle changes in [AMP]:[ATP] and AMPKα T172 phosphorylation is a more reliable indicator of 410 
changes in the AMP concentration than technically demanding direct measurements. Hence, it can be 411 
argued that a consensus emerges that metformin induces changes in hepatic energy status which is 412 
sufficient to modify the activity of sensors such as AMPK and FBP1. Nonetheless, we observed here a 413 
modest, but significant reduction in energy charge in response to metformin treatment in the liver, 414 
which may have partly contributed to suppression of energy-demanding gluconeogenic flux8. 415 
Understanding the mechanism by which metformin reduces HGP and normalizes blood 416 
glucose levels in hyperglycemic type 2 diabetics is of considerable importance. Our results show that 417 
metformin induces a mild energy stress in liver, leading to an increase in AMP concentration that 418 
allosterically inhibits FBP1 to lower HGP. This is potentially a powerful mechanism as the subsequent 419 
increase in F-1,6-P2 will activate PK and increase glycolytic flux46,47. Our study further supports the 420 
advancement of FBP1 as a key target for the treatment of type 2 diabetes, either directly using targeted 421 
inhibition48 or indirectly, as a consequence of inducing energy stress. The later mechanism may 422 
contribute significantly to the apparent glucose lowering effect of many biologically active secondary 423 
metabolites and to novel antidiabetic drugs exploiting the emerging concept of mild mitochondrial 424 
uncoupling49. 425 
 426 
METHODS 427 
Methods and any associated references are available in the online version of the manuscript. 428 
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FIGURE LEGENDS 572 
Figure 1. Generation of an AMP-insensitive FBP1 knockin mouse model. (a) Human FBP1 573 
structure (PDBID 1FTA) represented as ribbons and AMP and interacting residues (numbered from 574 
the initiator methionine) are shown as sticks. Dashed lines represent hydrogen bonding interactions, 575 
whereas residues making hydrophobic contracts are illustrated as sticks and transparent surfaces. Red 576 
and blue spheres represent backbone oxygen and nitrogen atoms respectively. (b) Coomassie-stained 577 
SDS-PAGE of mouse liver FBPase and recombinant mouse 6HIS-FBP1 preparations with single point 578 
mutations designed to disrupt AMP binding. (c) AMP inhibition curves of mouse 6HIS-FBP1 mutants. 579 
FBPase activity is expressed as a ratio of the maximum activity in the absence of AMP (V/Vo). IC50 580 
values represent the mean ± SD of three independent measurements on two enzyme preparations. The 581 
line graph is representative of the results from a single preparation. (d) Schematic illustrating the 582 
targeting strategy used to generate C57BL/6NTac FBP1G27P knockin (KI) mice. Exons and FRT 583 
recombination sites are represented by dark grey boxes and triangles respectively. The KI allele 584 
containing the G27P mutation in exon 1 is shaded pale grey. Correct recombination was confirmed by 585 
Southern blotting of PsiI and KpnI digests of genomic DNA isolated from targeted embryonic stem 586 
cells with the corresponding 5’ and 3’ probes (black boxes). Genotyping of the constitutive KI allele 587 
was performed by PCR of genomic DNA using primers P1 and P2. (e) Liver biopsies from overnight 588 
fasted (16 h) or refed (4 h) FBP1WT/WT (WT) or FBP1G27P/G27P (KI) mice were assayed for Fbp1 mRNA 589 
expression by qPCR (left chart) or FBPase activity (right chart) by spectrophotometric assay. The line 590 
graph (below) represents AMP inhibition curves of FBPase activity in liver homogenates expressed as 591 
a ratio of the activity in the absence of AMP (V/Vo). Results represent mean ± SD, n = 5-7 per group. 592 
 593 
Figure 2. FBP1 G27P knockin mice display normal glucose homeostasis. (a-e) FBP1WT/WT (WT) or 594 
FBP1G27P/G27P (KI) mice were fasted overnight for 16 h (Fasted) or subsequently given free access to 595 
standard chow for 4 h (Refed). Blood and liver biopsies were taken and the following parameters 596 
determined: blood glucose (a), plasma insulin (b), plasma glucagon (c), plasma leptin (d) and liver 597 
glycogen (e). n = 5-7 (WT) and 5-7 (KI) per group. (f) Glucose (2 g.kg-1 p.o.) and (g) pyruvate (1 g.kg-598 
1 i.p.) tolerance was assessed on mice fasted for 16 h. Results represent mean ± SE, n = 10 per group. 599 
(h) Expression of the major enzymes and regulatory components of the gluconeogenic, glycogenic and 600 
glycogenolytic pathways in liver samples from fasted or refed animals was determined by Western 601 
blotting. Representative results from three mice per group are shown. *P < 0.05 (Fasted vs. refed). 602 
Statistical significance was determined using unpaired, two-tailed Student’s t-test and an alpha level of 603 
0.05.  604 
 605 
Figure 3. FBP1 G27P KI mice are resistant to the hypoglycemic action of an AMP-mimetic 606 
FBPase inhibitor. (a) Diagram showing the structure of MB06322 and the active metabolite, 607 
MB05032. (b) Mouse and rat FBP1 preparations were assayed for inhibition by AMP (closed 608 
symbols) and MB05032 (open symbols). Results represent mean ± SD, n = 3. *P < 0.05 (Mouse vs. 609 
rat) (c-g) Vehicle (10:10:80 Solutol HS 15:PEG 400:water) or MB06322 (75 mg.kg-1 i.p.) was 610 
administered to fasted (16 h) WT (c) or KI (f) mice and blood glucose monitored at the indicated 611 
intervals for 3 h. (d, g) Lactate was measured just prior to drug administration and at t = 120 min using 612 
a lactate meter. (e) Plasma levels of MB05032 were assayed from blood samples drawn at the end of 613 
the protocol (t = 180 min). Results represent mean ± SE, n = 4-5 per treatment group. *P < 0.05 614 
(Vehicle vs. MB06322). Statistical significance was determined using unpaired, two-tailed Student’s t-615 
test and an alpha level of 0.05.  616 
 617 
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Figure 4. FBP1 G27P KI mice are resistant to the hypoglycemic action of AICAR. (a) Diagram 618 
illustrating the structure of AMP and ZMP. (b-l) AICAR tolerance was determined by administering 619 
vehicle (0.9 % saline) or AICAR (250 mg.kg-1- i.p.) to fasted (16 h) WT (b, e, g, i) or KI (c, f, h, j) 620 
mice. Blood glucose was measured at the indicated timepoints for a period of 3 h. (d) Plasma AICAR, 621 
(e, f) blood lactate, (g, h) plasma glucagon and (i, j) plasma insulin were assayed from blood samples 622 
drawn at t = 60 min. Results represent mean ± SE, n = 4-8 per treatment group. *P < 0.05 (Vehicle vs. 623 
AICAR). #P < 0.05 (WT vs. KI). (k, l) Vehicle (0.9 % saline) or AICAR (250 mg.kg-1- i.p.) was 624 
administered to fasted (16 h) mice and after 60 min exposure, liver biopsies were taken and assayed 625 
for AMPK activation by Western blotting. The blot image depicts three representative mice from each 626 
treatment group and a quantitative analysis of pT172 AMPKα phosphorylation from the entire sample 627 
set is shown in (l). Results are expressed as pT172 AMPKα/AMPKα ratio normalized to the WT-628 
vehicle group. n = 4-5 per treatment group. *P < 0.05 (Vehicle vs. AICAR). Statistical significance 629 
was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05.  630 
 631 
Figure 5. FBP1 G27P KI mice exhibit resistance to the acute glucose-lowering effect of 632 
metformin. (a, b) Vehicle (water) or metformin (250 mg.kg-1 p.o.) was administered to fasted (16 h) 633 
mice and after 45 min, glucose tolerance (2 g.kg-1 i.p.) was assessed by monitoring blood glucose over 634 
a period of 2 h. Results represent mean ± SE, n = 18 (WT-vehicle), 17 (WT-metformin), 15 (KI-635 
vehicle) and 15 (KI-metformin). *P < 0.05 (vehicle vs. metformin). (c-e) Mice were fasted for 16 h 636 
and dosed with vehicle (water) or metformin (250 mg.kg-1 p.o.). After 1 h exposure, blood and liver 637 
biopsies were taken and assayed for metformin (c). (d) Western blotting of ACC and AMPKα 638 
phosphorylation in livers from vehicle and metformin-treated mice. Representative results from three 639 
mice per group are shown. (e) Quantitative analysis of pT172 AMPKα. Results are expressed as 640 
pT172 AMPKα/AMPKα ratio normalized to the WT-vehicle group. n = 5. (f) Arterial blood glucose 641 
and glucose infusion rate (GIR) (g) during metformin-euglycemic clamps in FBP1WT/WT (WT) or 642 
FBP1G27P/G27P (KI) mice. Animals were fasted for 5 h and infused i.v. with metformin (3.75 mg.kg-643 
1.min-1) and a variable infusion of 50 % glucose to maintain euglycemia at 120 mg.dl-1 over a period of 644 
120 min. *P < 0.05 (WT vs. KI). (h) Plasma and liver metformin concentrations at the end of the 645 
clamp period. (i-l) Rates of endogenous glucose production (EndoRa) (i), gluconeogenesis (GNG) (j), 646 
glycogenolysis (GYG) (k) and glucose disappearance (Rd) (l) during the resting period (5 h fasted) 647 
and steady state of the metformin clamp (average from 100-120 min). Results represent mean ± SE, n 648 
= 8 (WT-resting), 8-9 (WT-clamp), 10 (KI-resting) and 9-11 (KI-clamp). *P < 0.05. Statistical 649 
significance was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05.  650 
 651 
Figure 6. FBP1 G27P KI mice are resistant to the glucose lowering effects of metformin in an 652 
obesity-induced model of diabetes. Body mass (a) and cumulative food intake (b) for FBP1WT/WT 653 
(WT) and FBP1G27P/G27P (KI) fed a 60 % Kcal high fat diet ad libitum over a period of eight weeks. (c-654 
f) Glucose tolerance (1.5 g.kg-1 i.p.) (Glycemia in c and corresponding AUC in d), plasma insulin (e) 655 
and triglyceride (TG) (f) were assessed after eight weeks of dietary intervention. Results represent 656 
mean ± SE (a-c), n = 10-12 per group. (g, h) After 10 weeks of dietary intervention mice were fasted 657 
for 16 h, administered vehicle (water) or metformin (250 mg.kg-1 p.o.) and blood glucose measured 658 
after 2 h. n =13 (WT-vehicle), 15 (WT-metformin), 8 (KI-vehicle) and 12 (KI-metformin). *P < 0.05 659 
(Vehicle vs. metformin). #P < 0.05 (Resting vs. 120 min) (i-k) After 12 weeks of dietary intervention 660 
mice were fasted for 16 h, administered vehicle (water) or metformin (250 mg.kg-1 p.o.) and liver 661 
biopsies were taken after 2 h of drug treatment. Liver metformin (i), pT172 AMPKα phosphorylation 662 
(expressed as pT172 AMPKα/AMPKα ratio normalized to the WT-vehicle group) (j), and cAMP (k) 663 
are shown. n = 6-7 (WT-vehicle), 6 (WT-metformin), 6-7 (KI-vehicle) and 6 (KI-metformin). *P < 664 
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0.05 (Vehicle vs. metformin). #P < 0.05 (WT vs KI). Statistical significance was determined using 665 
unpaired, two-tailed Student’s t-test and an alpha level of 0.05.  666 
  667 
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Online Methods 668 
 669 
Materials 670 
 671 
E.coli strain DF657 was sourced from the CGSC (Coli Genetic Stock Centre, Yale University) and 672 
BL21-CodonPlus(DE3)-RIL were from Agilent. Casamino acids were from BD Biosciences. Talon® 673 
cobalt IMAC resin was from Clontech. P11 and P81 phosphocellulose and BA-85 nitrocellulose were 674 
from Whatman. Leupeptin, pepstatin A and isopropyl-β-D-thiogalactopyranoside (IPTG) were from 675 
Serva. GST-HRV3C protease was from the Division of Signal Transduction Therapy (DSTT, 676 
Dundee). Fructose-2,6-bisphosphate (F-2,6-P2) (30 % purity) was from Toronto Research Chemicals. 677 
Higher purity F-2,6-P2 was kindly provided by Mark Rider (Université catholique de Louvain, 678 
Belgium). FBPase-1 inhibitor was from Santa Cruz. MB06322 was synthesised by SpiroChem 679 
(Zurich, Switzerland) as previously described1. MB05032 was from MedChem Express. 1-methoxy-5-680 
methylphenazinium methyl sulfate was from Applichem. Sypro Orange and sterile 20 % (w/v) glucose 681 
were from Life Technologies. 2’,3’-O-trinitrophenyl-adenosine-5’-monophosphate (TNP-AMP), 682 
2’/3’-O-(2-aminoethyl-carbamoyl)-adenosine-5’-monophosphate (2’/3’-EDA-AMP)-agarose and Z 683 
(AICAR) nucleotide standards were from Jena Bioscience. KAPA2G Fast HotStart genotyping mix 684 
was from Kapa Biosystems. Metformin-HCl, 5,5-diphenylhydantoin, Solutol (Kolliphor) HS 15, PEG 685 
(Kollisolv) 400 and all HPLC-grade solvents and additives were from Sigma. Microcystin-LR was 686 
from Enzo Life Sciences. NADH and AICAR (5-amino-1-(β-D-ribofuranosyl)-1H-imidazole-4-687 
carboxamide) were from Apollo Scientific Ltd. Acetyl-CoA, trilithium salt was from Roche Life 688 
Science. Immobilon-P PVDF membrane was from Merck Millipore. Sephadex G-25, Blue Sepharose 689 
6 FF, Superdex 10/300 GL and enhanced chemiluminescent reagent were from GE Healthcare. [γ-32P]-690 
ATP, [U-14C]-uridine diphosphate glucose and [U-14C]-glucose-1-phosphate were from Perkin Elmer. 691 
2H2O and [6,6-2H2]-glucose were from Cambridge Isotope Laboratories (Tewksbury, MA). AMARA 692 
substrate peptide (NH2-AMARAASAAALARRR-COOH) was synthesized by GL Biochem 693 
(Shanghai). Chicken muscle was sourced from a local supermarket and rabbit muscle was purchased 694 
from Harlan UK Ltd. Unless otherwise stated, all other reagents were from Sigma. 695 
 696 
Antibodies 697 
 698 
PEPCK-M (#6924), pS641 GYS (#3891), GYS (#3886), pT389 p70S6K (#9234), p70S6K (#2708), 699 
pS240/244 S6 (#2215), S6 (#2217), pS79/S212 ACC1/2 (#3661), ACC1/2 (#3676), pT172 AMPKα1/2 700 
(#2535), AMPKα1/2 (#2532), AMPKα1/2 mAb (#2793), pT792 RAPTOR (#2083), RAPTOR 701 
(#2280), Fas (#3180), HXK1 (#2024), G6PD (#12263), TBC1D1 (#4629), pS133 CREB (#9198) and 702 
streptavidin-HRP (#3999) were from Cell Signaling Technology. G6PT (sc-135479) and FBP1 (sc-703 
32435) were from Santa Cruz Biotechnology. PFKL (ab181064), PKLR (ab171744) and PEPCK-C 704 
(ab28455) were from Abcam. GAPDH (G8795) and α-tubulin (T6074) were from Sigma. 705 
SLC22A1/OCT1 (#ACT-011) antibody was from Alomone Labs. pS237 TBC1D1 was from Merck 706 
Millipore (07-2268). PYGL (15851-1-AP) was from Proteintech. pS15 PYGL (S961A) was from 707 
DSTT. AMPKα1 and AMPKα2 antibodies used for immunoprecipitation were raised in sheep against 708 
C-355TSPPDSFLDDHHLTR369 and C-352MDDSAMHIPPGLKPH366 (human sequences) respectively. 709 
GLUT2 antibody was provided by Bernard Thorens (University of Lausanne, Switzerland). 710 
GCK/HXK4 antibody was provided by Mark Magnuson (Vanderbilt University, TN). GCKR antibody 711 
was from Masakazu Shiota (Vanderbilt University, TN). G6PC antibody was provided by Giles 712 
Mithieux (University of Lyon, France). pS33 PFKFB1 antibody was provided by Jianxin Xie (Cell 713 
Signaling Technology). PFKFB1 antibody was provided by Simone Baltrusch (University of Rostock, 714 
Germany). pS8 GYS2 antibody was provided by Joan Guinovart (University of Barcelona, Spain). 715 
HRP-coupled and Alexa Fluor 680/Alexa Fluor 790-labelled secondary antibodies were from Jackson 716 
Immunoresearch.  717 
 718 
  719 
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Primers. Oligonucleotides were synthesized by Life Technologies. 720 
 721 
Genotyping primers for C57BL/6NG27P mice:  722 
for-TGACAGTTAAGATTCTGCTCTGC, rev-TTAGGGATGATACTGAATTAGAAGC 723 
 724 
Target Forward Reverse 
Fasn AGCGGCCATTTCCATTGCCC    CCATGCCCAGAGGGTGGTTG 
Fbp1 GTGTCAACTGCTTCATGCTG    GAGATACTCATTGATGGCAGGG 
Foxo1a CTACGAGTGGATGGTGAAGAGC    CCAGTTCCTTCATTCTGCACTCG 
G6pc ACTGTGGGCATCAATCTCCTC     CGGGACAGACAGACGTTCAGC 
Gck GCATCTCTGACTTCCTGGACAAG    CTTGGTCCAGTTGAGCAGGATG 
Pck1 CCATCACCTCCTGGAAGAACA        ACCCTCAATGGGTACTCCTTCTG 
Pparg1c ATACCGCAAAGAGCACGAGAAG    CTCAAGAGCAGCGAAAGCGTCACAG 
18S GTAACCCGTTGAACCCCATT    CCATCCAATCGGTAGTAGCG 
 725 
Cloning and mutagenesis. Mouse Fbp1 (NCBI reference AJ132693.1) was amplified from IMAGE 726 
EST 5054854 using KOD Hot Start DNA Polymerase (Merck Millipore) and cloned into the BamHI 727 
NotI sites to produce pET28a 6HIS-FBP1 and pET15 6HIS-HRV3C-FBP1. Mutations were created 728 
following the QuikChange method (Agilent) but using KOD Hot Start DNA Polymerase. The 729 
phosphatase domain of mouse 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 (NCBI 730 
reference NM_008824.3) covering amino acids 251-440 was amplified from mouse liver RNA 731 
(Agilent #736009-41) using GoTaq 1-step RT-qPCR kit (Promega). The resulting PCR product was 732 
ligated into pGEX-6P-1 vector (GE Healthcare) as a Bamh1-Not1 fragment. Spinach chloroplast 733 
fructose-1,6-bisphosphatase 58-415 was cloned from a synthetic fragment (GeneArt Strings, based on 734 
Uniprot P22418) and ligated into a modified pET-15b plasmid as a Bamh1-Not1 fragment. The 735 
sequence of all constructs was verified by in-house sequencing using the BigDye® Terminator 3.1 kit 736 
on a 3500xL Genetic analyzer (ABI-Invitrogen). 737 
 738 
Preparation of rFBP1. 6HIS-FBP1 was expressed in the Fbp-null E.coli strain, DF657(DE3) as 739 
described by Giroux2. DF657 was sourced from the CGSC (Yale University, CT) and the DE3 lysogen 740 
prepared using the λDE3 lysogenization kit (Novagen #69734). Cells were transformed with pET28a 741 
FBP1 and cultured in minimal media (M9 salts, 2 mM MgSO4, 0.4 % (w/v) glycerol, 5 μg/ml 742 
thiamine-HCl, 0.5 % (w/v) casamino acids and 50 μg/ml kanamycin) overnight at 37ºC. Minimal 743 
media (0.5 – 1 L containing 25 μg/ml kanamycin) was inoculated 1:40 with the starter culture and 744 
induced with 0.4 mM IPTG at OD600 ~ 0.4 for 16 h at 37ºC. Cells were lysed in 5 ml/g 50 mM 745 
phosphate pH 7, 150 mM NaCl, 0.5 mM TCEP, 0.2 mM PMSF and 5 μg/ml leupeptin by sonication (1 746 
min, 40 % amplitude) and clarified at 20,000 g for 20 min at 4ºC. 6HIS-FBP1 was batch bound to Co+-747 
charged IMAC resin (Talon®) for 30 min at 4ºC, washed with 10 vol. lysis buffer, 10 vol. 5 mM 748 
imidazole and eluted with 5 vol. 150 mM imidazole. Preparations were exchanged into 50 mM 749 
imidazole pH 7.4, 0.3 M KCl, 0.2 mM EDTA and 0.5 mM TCEP over Sephadex G-25, concentrated 750 
using 10 kD MWCO centrifugal devices (Sartorius Vivaspin) and stored at –20ºC in 50 % (v/v) 751 
glycerol. The presence of imidazole in concentrated solutions of 6HIS-FBP1 was essential to prevent 752 
aggregation. Untagged FBP1 was prepared by on-column cleavage of 6HIS-LEVLFQ*GPGS-FBP1 753 
(constructed in pET15 and prepared as described above) with 50 μg HRV-3C protease per mg 6HIS-754 
FBP1 in 50 mM TES pH 7.4, 150 mM KCl, 0.5 mM TCEP. Preparations were polished over a 755 
Superdex 200 10/300GL column equilibrated with 50 mM TES pH 7.4, 0.3 M KCl, 1 mM DTT and 756 
stored at –20°C in 50 % (v/v) glycerol. Preparations were stable for at least 6 months. As a reference, 757 
FBPase was purified from mouse liver essentially as described by Tashima3. Briefly, 20 g liver from 758 
C57BL/6N mice was homogenized in four volumes of 20 mM phosphate pH 7, 150 mM KCl, 1 mM 759 
EDTA, 1 mM DTT, 0.5 mM PMSF, 2 μg/ml leupeptin and clarified at 10,000 g for 20 min at 4ºC. The 760 
supernatant was subjected to heat denaturation at 60ºC for 1 min and centrifuged at 20,000 g for 20 761 
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min at 4ºC.  The supernatant was subjected to a 55-75 % ammonium sulfate cut and the resulting pellet 762 
dissolved in 1 mM EDTA and dialyzed overnight against 10 mM sodium malonate pH 6.2, 1 mM 763 
EDTA (Buffer A). FBPase was batch bound to 30 g P11 phosphocellulose, washed with 300 ml Buffer 764 
A under suction and transferred to an XK26/20 column. The resin was washed with buffer A 765 
containing 50 mM NaCl until A280 < 0.01 and FBPase was eluted with 2 mM fructose-1,6-766 
bisphosphate (F-1,6-P2) and 20 μM 5’-adenosine monophosphate (AMP). Positive fractions were 767 
dialyzed against Buffer A, the pH adjusted to 5.8 with malonic acid and applied to a 1.6 × 10 cm 768 
column of Blue Sepharose FF (C16/20). The column was washed with 10 mM sodium malonate pH 769 
5.8, 1 mM EDTA and eluted with 1 mM F-1,6-P2 and 1 mM AMP. The preparation was polished over 770 
a Superdex 200 10/300GL column equilibrated with 20 mM phosphate pH 7, 150 mM KCl, 1 mM 771 
EDTA and stored in 50 % (v/v) glycerol at –20ºC. 772 
 773 
FBPase assay. Fructose-1,6-bisphosphatase (EC 3.1.3.11) activity was determined by monitoring the 774 
formation of fructose-6-phosphate (F6P) using a coupled spectrophotometric assay. The specific 775 
activity of rFBP1 was determined in 1 ml reactions containing 50 mM TES pH 7.4, 0.2 mM NADP+, 776 
0.1 M KCl, 0.05 mM EDTA, 2 mM (NH4)2SO4, 2 mM MgCl2, 0.05 % (w/v) BSA, 2 mM 2-777 
mercaptoethanol, 0.8 U/ml phosphoglucose isomerase and 0.5 U/ml glucose-6-phosphate 778 
dehydrogenase. Reactions were started by the addition of 35 µM F-1,6-P2 and A340 recorded in a Cary 779 
100 spectrophotometer at 30ºC. Reaction rates were calculated from the linear phase assuming 780 
ε(NADPH) = 6.22 mM-1.cm-1. 1 U is defined as 1 μmol F6P formed per min at 30ºC. Where 781 
appropriate, 1 U/ml AMP deaminase (purified from chicken muscle using P11 phosphocellulose 782 
essentially as described by Smiley4) was included to remove contaminating AMP from NADP+ as 783 
described by Han5. The activity ratio at pH 7.2/9.4 was determined under similar conditions in 784 
reactions buffered with 50 mM bis-tris propane at the appropriate pH. Other kinetic properties were 785 
determined in a 96 well format in non-binding black microplates (Greiner #655900), where the 786 
quantity of NADP+ was reduced to 0.15 mM and reactions were monitored by the increase in 787 
fluorescence (λex = 345 nm, λem = 465 nm) calibrated by the addition of 5 nmol F6P. Km(F-1,6-P2) was 788 
determined at 2 mM Mg2+ and fitted to equation 1: 789 
 790 
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Where: V = initial velocity, Vm = maximum velocity, [S] = F-1,6-P2 conc., Km = Michaelis constant for S, Ks = 793 
apparent substrate inhibition constant and b = factor determining maximum activity at high [S].
 
794 
 795 
Km(Mg2+) was determined at 35 μM F-1,6-P2 and fitted to equation 2: 796 
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 799 
Where: V = initial velocity, Vm = maximum velocity, [S] = Mg2+ conc., Km = Michaelis constant for S and h = 800 
hill coefficient. 801 
 802 
IC50 for inhibitory compounds was determined at 2 mM Mg2+, 35 μM F-1,6-P2 and fitted to equation 3: 803 
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Where: V = initial velocity, V0 = maximum velocity in the absence of inhibitor, I = conc. inhibitor, I0.5 = conc. of 806 
inhibitor that gives 50 % inhibition and h = hill coefficient. 807 
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Stock solutions of F-1,6-P2 were standardized by enzymatic assay in reactions containing 50 mM 808 
imidazole pH 7, 0.15 mM NADH, 0.02 U/ml aldolase, 1.2 U/ml triosephosphate isomerase and 0.16 809 
U/ml glycerol-3-phosphate dehydrogenase. Stock solutions of AMP, 5’-inosine monophosphate (IMP) 810 
and 5’-AICAR monophosphate (ZMP) were prepared in 20 mM TES pH 7.4, neutralized with NaOH 811 
and standardized by UV absorbance in 0.1 M phosphate pH 7 at A259 (εAMP = 15.4 mM-1.cm-1), A249 812 
(εIMP = 12 mM-1.cm-1) and A265 (εZMP = 12.5 mM-1.cm-1) respectively. F-2,6-P2 is difficult to obtain 813 
commercially and the crude product available from Toronto Research Chemicals was solubilized in 10 814 
mM NaOH and standardized in reactions containing 50 mM HEPES pH 7.1, 5 mM MgCl2, 0.1 mM 815 
EDTA, 0.15 mM NADP+ by sequential addition of 0.1 U/ml glucose-6-phosphate dehydrogenase, 0.2 816 
U/ml phosphoglucose isomerase and 0.25 U/ml GST-FBPase-2 P251-N440 while recording the 817 
increase in A340. 818 
 819 
Thermal Stability Assays. TSA was performed on untagged FBP1 preparations using a Roche 820 
LightCycler 480 II. FBP1 was diluted to 0.2 mg/ml in 20 mM HEPES pH 7.4, 100 mM KCl, 1 mM 821 
MgCl2 and the indicated ligands and 5× Sypro Orange added sequentially. Solutions (20 µl) were 822 
dispensed in quadruplicate into 384-well white plates, sealed with optical tape and centrifuged at 200 g 823 
for 1 min. Fluorescence (λex – 465 nm, λem – 580 nm, Melt factor = 1, Quant factor = 10) was 824 
monitored while the block temperature was ramped from 20ºC to 95ºC at ~1ºC/min (24 acquisitions/ºC 825 
in continuous mode). The melting temperature (Tm) was determined from the maximum of the first 826 
derivative of the raw data using Roche Protein Melting software. 827 
 828 
TNP-AMP fluorescence spectroscopy. Titration of 2’,3’-O-trinitrophenyl-adenosine-5’-829 
monophosphate (TNP-AMP) was determined as described by Nelson6 using 1 µM FBP1 in 50 mM 830 
tris-acetate pH 7.4, 5 mM F6P, 5 mM Pi and 2 mM MgCl2 at 25ºC. Raw fluorescence (λex = 410 nm, 831 
λem = 535 nm) was corrected for dilution and inner filter effects using equation 4: 832 
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 835 
Where Fcorr is the corrected fluorescence, V is the volume at a specific titration point and V0 is the initial volume. 836 
 837 
Data were analyzed by non-linear regression to equation 5: 838 
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 841 
Where ΔF is the change in fluorescence caused by the addition of ligand (L), Fo is the initial fluorescence in the 842 
absence of ligand, Kd is the dissociation constant of L and h is the hill coefficient. 843 
 844 
Immobilized ligand affinity binding. FBP1 (2 µg) in 20 mM TES pH 7.4, 100 mM KCl, 1 mM 845 
MgCl2, 0.1 mM F-1,6-P2 and 0.01 % (w/v) BRIJ-35 was mixed with 5 µl 2’/3’-O-(2-aminoethyl-846 
carbamoyl)-adenosine-5’-monophosphate (2’/3’-EDA-AMP)-agarose or unconjugated agarose for 30 847 
min at 4ºC. Excess free ligand (0.5 mM AMP) was included as a negative control. Resin was pelleted 848 
at full-speed for 5 s, washed 3× 0.5 ml binding buffer and eluted with 20 µl Laemmli sample buffer. 849 
Samples were denatured at 95ºC for 2 min, fractionated by SDS-PAGE and stained with colloidal 850 
Coomassie G-250. 851 
 852 
  853 
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Animals. Animal studies were approved by the local ethics committee and all protocols were 854 
approved by the Service Vétérinaire Cantonal (Lausanne, Switzerland) under license VD2841. 855 
C57BL/6NTac FBP1G27P mice were generated by Taconic Biosciences GmbH as described in Fig. 1d. 856 
Animals were kept in a standard temperature and humidity controlled environment on a 12/12 h 857 
light/dark cycle and had free access to water and standard chow or 60 kcal% fat diet (Research Diets 858 
Inc. D12492) as described. [11C]-metformin positron emission tomography (PET) was performed in 859 
accordance with the Danish Animal Experimentation Act and the European convention for the 860 
protection of vertebrate animals used for experimental and other purposes and was approved by the 861 
Animal Experiments Inspectorate, Denmark. Metformin-euglycemic clamps were completed with the 862 
approval of the Vanderbilt Animal Care and Use Committee. Animals were housed on a 12/12 h 863 
light/dark cycle in a temperature (23°C) and humidity-stable environment. Mice were maintained on a 864 
standard chow diet (5L0D LabDiet, St. Louis, MO). Male mice between the ages of 14-22 weeks were 865 
used for all procedures. Basic phenotyping was performed by PhenoPro (Illkirch, France) in a licensed 866 
animal facility (agreement #A67-218-40). All experiments were approved by the local ethical 867 
committee (Com’Eth, accreditations #2014-011), and were supervised by B.P.D. or M.F.C. who are 868 
qualified in compliance with the European Community guidelines for laboratory animal care and use 869 
(2010/63/UE). For glucose tolerance test, pyruvate tolerance test, metformin tolerance test, AICAR 870 
injection and MB06322 injection, the appropriate sample size was estimated to be 8-10 based on a 871 
power calculation assuming α = 0.05, power = 0.8 and variance from previous studies. However, 872 
based on pilot experiments, responses to some of the compounds were much larger than anticipated 873 
and less animals were required as indicated in figure legends. Animals were arbitrarily but not 874 
randomly assigned to experimental groups and investigators were unblinded.  875 
 876 
Tissue homogenization. Liver biopsies were powdered in a liquid nitrogen cooled mortar and pestle 877 
and homogenized in 10 volumes of extraction buffer using a rotor-stator homogenizer (Polytron, 878 
Kinematica AG). For Western blotting and assay of G6PC, PK and FBP1, tissues were homogenized 879 
in 50 mM tris-HCl pH 7.5, 0.27 M sucrose, 1 mM EDTA, 1 % (w/v) Triton X-100, 20 mM glycerol-2-880 
phosphate, 50 mM NaF, 5 mM Na4P2O7, 0.5 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 881 
µg/ml aprotinin, 1 µM microcystin-LR, 1 mM DTT and clarified at 3500 g for 5 min at 4ºC. Glycerol-882 
2-phosphate was omitted for extracts used for assay of GS and GP. DTT was omitted for extracts 883 
prepared for the assay of CS and PC. For GCK, PFK and PEPCK-C assays, tissues were gently 884 
homogenized in 50 mM HEPES-KOH pH 7.4, 100 mM KF, 15 mM EGTA, 5 % (w/v) glycerol, 1 885 
µg/ml leupeptin, 1 µg/ml pepstatin A, 1 µg/ml aprotinin and 5 mM DTT and centrifuged at 100,000 g 886 
for 30 min to prepare a cytosolic fraction free of mitochondrial and microsomal fragments. Skeletal 887 
muscle biopsies were powdered in a liquid nitrogen cooled Bessman pulverizer and homogenized in 888 
10 volumes of Triton X-100 extraction buffer supplemented with 50 mM KCl to prevent gelling. 889 
 890 
Western blotting. Tissue extracts were denatured in Laemmli buffer at 95ºC for 2 min, fractionated 891 
by tris-glycine SDS-PAGE and transferred to PVDF membrane at 100 V for 1 h in Towbin buffer (25 892 
mM tris, 192 mM glycine, 10 % (v/v) methanol). Membranes were blocked with 5 % (w/v) skimmed 893 
milk in TBS-T (20 mM tris-HCl pH 7.5, 137 mM NaCl, 0.1 % (v/v) Tween-20) for 1 h at room 894 
temperature and incubated in primary antibodies prepared in TBS-T containing 5 % (w/v) BSA 895 
overnight at 4ºC. Membranes were developed using HRP-conjugated secondary antibodies and ECL 896 
reagent. For integral membrane proteins (GLUT2, G6PC and G6PT) samples were not boiled, but 897 
heated at 37ºC for 30 min. Pyruvate carboxylase was detected using HRP-conjugated streptavidin. 898 
OCT1 (SLC22A1) was detected by immunoprecipitation from 200 µg detergent extracts with 2 µg 899 
anti-OCT1 (Alomone ACT-011) and 5 µl protein G-Sepharose for 2 h at 4ºC. Immune complexes 900 
were washed 3× 1 ml lysis buffer and eluted with 20 µl Urea-SDS sample buffer (62.5 mM tris-HCl 901 
pH 6.8, 2 % (w/v) SDS, 0.5 mM EDTA, 6 M urea, 0.01 % (w/v) bromophenol blue and 10 % (w/v) 902 
glycerol) for 1 h at RT. Specificity of detection was confirmed using liver extracts from OCT1 KO 903 
mice (provided by Niels Jessen, Aarhus University Hospital, Denmark). Quantitative blotting was 904 
performed using detection with either infrared fluorescent secondary antibodies (AF680 and AF790) 905 
on nitrocellulose membranes using an Odyssey CLx infrared imaging system (Li-COR) or developed 906 
films following ECL detection were scanned and quantitated by densitometry using ImageJ. 907 
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Metabolic phenotyping. Mice were weighed and food consumption monitored on the same day. Mice 908 
were starved for 16 h, starting at 17:00 on the previous day so that all procedures commenced at 09:00 909 
the following morning. Blood glucose was monitored using a glucometer (AlphaTRAK 2, Abbott 910 
Logistics B.V.) on venous blood drawn from the tail. Blood lactate was assayed using a meter (Lactate 911 
Pro 2, Arkray Inc.). The genotype of experimental animals was confirmed by PCR on 1 µl blood lysed 912 
in 20 µl 20 mM NaOH, 60 % (w/v) PEG-2007 using KAPA2G polymerase. Glucose tolerance was 913 
determined by administration of 2 g.kg-1 D-glucose p.o. or i.p. from a 20 % (w/v) glucose solution 914 
after 16 h fast. Pyruvate tolerance was determined by administration of 1 g.kg-1 pyruvate (free acid) 915 
i.p. from a 12.7 % (w/v) sodium pyruvate solution (pH 6) after a 16 h fast. The pyruvate stock solution 916 
was standardized by assay in 50 mM phosphate pH 7, 0.15 mM NADH and 0.1 U/ml lactate 917 
dehydrogenase. AICAR tolerance was determined by administration of 250 mg.kg-1 i.p. from a 12.5 918 
mg.ml-1 solution in 0.9 % (w/v) saline after a 16 h fast. The acute glucose lowering effect of MB06322 919 
was assessed by administration of 75 mg.kg-1 i.p. from a 7.5 mg.ml-1 solution in a vehicle composed of 920 
10:10:80 Solutol HS 15:PEG 400:water (Compound was dissolved in PEG 400 by gentle 921 
heating/sonication, combined with warm liquid Solutol HS 15 and dispersed in water). Energy 922 
expenditure, food intake and spontaneous activity (beam-break) was determined by indirect 923 
calorimetry (Labmaster, TSE Systems GmbH, Germany). Following a 3 h acclimatization period, mice 924 
were monitored for a 21 h period from 14:00 on day 1 to 23:00 on day 2 (12/12 h light/dark cycle at 925 
21±2°C). 926 
 927 
Plasma metabolites. Blood was drawn by tail bleeding into lithium heparin coated capillaries 928 
(Sarstedt Microvette CB-200) and plasma prepared by centrifugation at 3,000 g for 5 min at 4ºC. 929 
Plasma was stored at -80ºC prior to analysis. Insulin and glucagon were determined by sandwich 930 
ELISA using kits from Mercodia (#10-1249-01 and #10-1281-01). Leptin was measured using an 931 
ELISA from Merck Millipore (#EZML-82K). Triglyceride was determined using an enzymatic assay 932 
from Sigma (TR0100). 933 
 934 
Metformin tolerance test. Animals were starved for 16 h and 250 mg.kg-1 metformin-HCl 935 
administered p.o. by gavage. After 45 min, resting blood glucose (t = 0) was recorded and 2 g.kg-1 936 
glucose was administered i.p. Blood glucose was monitored at t = 20, 40, 60 and 120 min. At the end 937 
of the procedure ~30 µl of blood was drawn into heparinized capillaries for determining plasma 938 
metformin concentration. 939 
 940 
Metformin assay. Metformin was assayed in plasma and tissues by ion-pair reverse phase 941 
chromatography on a Dionex Ultimate-3000 RS HPLC essentially as described by Zarghi8. Plasma 942 
was deproteinized with three volumes 80 % (v/v) acetonitrile containing 5 µg/ml 5,5-943 
diphenylhydantoin as internal standard. Protein was pelleted at 10,000 g for 5 min and the supernatant 944 
used directly. Standards were prepared by spiking metformin (1 mg/ml standard prepared in methanol 945 
and stored at 4ºC) into drug-free heparinized plasma (Innovative Research Inc. #IMS-C57BL6-N) so 946 
that the final concentration after solvent extraction ranged from 0.3 to 5 µg/ml. Tissue samples were 947 
powdered in a liquid nitrogen cooled mortar and pestle and homogenized with 10 volumes 10 mM 948 
NaOH using a bead mill (Qiagen TissueLyser II, 2×2 min at 30 Hz) and 100 µl was extracted with 1 949 
ml 1:1 acetonitrile:methanol containing 5 µg/ml 5,5-diphenylhydantoin. Samples were centrifuged at 950 
16,000 g for 10 min and 0.3 ml supernatant was evaporated in a Speedvac at 45ºC. The residue was 951 
dissolved in 100 - 200 µl 40 % (v/v) acetonitrile and particulate material removed by centrifugation 952 
before analysis. Standards were prepared by spiking metformin into alkaline tissue extracts from drug-953 
free animals so that the final concentration ranged from 0.3 to 5 µg/ml. Samples and standards (20 µl) 954 
were injected onto a Syncronis 150×4.6 mm, 5 µm C18 column (Thermo 97105-154630) with a 955 
10×4.0 mm guard column (Thermo 97105-014001) equilibrated with mobile phase containing 10 mM 956 
NaH2PO4, 10 mM SDS pH 5.1 and 40 % (v/v) acetonitrile at 1.3 ml/min at 26ºC. Metformin and 5,5-957 
diphenylhydantoin were resolved isocratically with retention times of 4.0 and 4.4 min and monitored 958 
by UV absorbance (235 nm). Chromatograms were acquired and integrated using Chromeleon v7.1. 959 
Results for tissue metformin are uncorrected for blood contamination. For correction of apparent drug 960 
tissue concentrations for residual blood volume, tissues were homogenized in 10 volumes ice-cold 40 961 
mM potassium phosphate pH 8.1 and blood content determined by assaying the pseudoperoxidase 962 
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activity of haemoglobin9 in reactions containing 85 mM NaCl, 5.8 M acetic acid, 0.83 mM EDTA, 33 963 
mM chlorpromazine and 0.6 % H2O2 assuming an average haematocrit of 46.6 %. Reactions were 964 
monitored at A525 and a standard curve prepared using a reference sample of whole mouse blood 965 
collected in 4 mM EDTA. Metformin was extracted from homogenates in phosphate buffer and 966 
assayed as described above. 967 
 968 
AICAR assay. Blood was drawn into EDTA capillaries and immediately supplemented with 25 μM 969 
dipyridamole and 25 nM A13457 to prevent further uptake and metabolism of AICAR by 970 
erythrocytes10. Plasma was deproteinized with three volumes 0.4 N PCA and pelleted at 16,000 g for 5 971 
min at 4ºC. Supernatant was neutralized with 0.16 volumes 2 N KHCO3 and solid KClO4 removed at 972 
16,000 g for 5 min. Standards were prepared by spiking AICAR into drug-free plasma in the range 0 – 973 
100 μM. Samples/standards (20 μl) were injected onto a Syncronis 150×4.6 mm, 5 µm C18 column 974 
with a 10×4.0 mm guard column equilibrated with mobile phase containing 95:5 10 mM phosphate pH 975 
8.2:acetonitrile at 1 ml.min-1 at 26ºC. AICAR was resolved isocratically with a retention time of 3.2 976 
min and monitored at A260. Chromatograms were acquired and integrated using Chromeleon v7.1 977 
 978 
MB05032 assay. Plasma was deproteinized with two volumes methanol and pelleted at 16,000 g for 979 
10 min at 4ºC. Standards were prepared by spiking MB06322 and MB05032 (1 mM solutions in 980 
methanol) into the methanol precipitant so that the effective plasma concentration ranged from 0 to 80 981 
μM. Samples and standards (20 µl) were injected onto a Syncronis 150×4.6 mm, 5 µm C18 column 982 
with a 10×4.0 mm guard column equilibrated with mobile phase (A – 20 mM phosphate pH 6.2, 10 % 983 
acetonitrile) at 1.5 ml.min-1 at 40ºC. The column was resolved with an acetonitrile gradient (B – 80 % 984 
acetonitrile): 0 min – 0 % B, 1 min – 0 % B, 13 min – 100 % B, 15 min – 0 % B and re-equilibrated 985 
with A for 8 min. Peaks were detected at A300. Water used for mobile phase preparation was filtered 986 
through Empore SBD-XC cartridge filters to remove impurities and improve baseline stability. 987 
Chromatograms were acquired and integrated using Chromeleon v7.1. 988 
 989 
 990 
Metformin-euglycemic clamp. Prior to the onset of the study an estimation of the required sample 991 
size was determined according to: 992 
 993 
n = (zα/2 + z1−β)2 (s•δ-1)2  994 
 995 
where the level of significance was α = 0.05 and desired power was 1-β = 0.8. The quantities zα/2 and 996 
z1−β are critical values from the normal distribution being 1.96 and 0.8416, respectively. The sampled 997 
standard deviation, s, has a value of 2 mg.kg-1.min-1. This quantity was used as initial studies in our 998 
laboratory using stable isotopes to quantify in vivo EndoRa in the fasted mouse provided a standard 999 
deviation of 2 mg.kg-1.min-1. δ (2 mg.kg-1.min-1) represents the difference we aimed to identify for 1000 
EndoRa. As such, the resulting sample size rounded off at n = 8. Experimenters were blinded to the 1001 
genotype until the conclusion of the study. Values were excluded from means reported based on the 1002 
following pre-determined exclusion criteria: 1003 
 1004 
1.  Following completion of metformin clamps for all mice designated for study the glucose infusion 1005 
rates (GIR) were assessed. Any mouse that displayed GIR outliers during the steady state sampling 1006 
period (100-120 minutes) was removed from any further analysis. Outliers were designated as those 1007 
with values ± 1.5 standard deviations from the group mean of a specific time point.  1008 
 1009 
2.  Estimated glucose fluxes (EndoRa, Rd, gluconeogenesis and glycogenolysis) were excluded from 1010 
reported means if the value was ± 2 standard deviations from the group mean.         1011 
 1012 
Mice were chronically catheterized approximately seven days prior to study, as described previously11. 1013 
Briefly, catheters were implanted in the carotid artery and jugular vein for sampling and infusing, 1014 
respectively. Animals were housed individually post-surgery and monitored for distress.  Prior to 1015 
study, mice were within 10 % of pre-surgery weight. On the day of study, mice were placed in bedded 1016 
containers without food or water at 07:00 (t = -300 min), five hours prior to initiation of the clamp. An 1017 
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arterial blood sample (80 μl) was drawn for evaluating the unlabeled, natural isotopic abundance of 1018 
glucose after three hours of fasting (t = -120 min). Subsequently, a bolus of 2H2O (99.9 %) was 1019 
delivered over 25 minutes to enrich total body water to 4.5 %. A [6,6-2H2]glucose prime (80 mg.kg−1) 1020 
was dissolved in the bolus. Following the prime, [6,6-2H2]glucose was continuously infused (0.8 1021 
mg.kg−1.min−1) for the remainder of the fasting period. An arterial blood sample (110 μl) was taken to 1022 
determine basal glucose kinetics, arterial glucose and insulin (t = -5 min). Metformin was delivered as 1023 
a continuous infusion (1.875 or 3.75 mg.kg−1.min−1) followed by a variable infusion of 50 % dextrose 1024 
(8 % [6,6-2H2]glucose) to clamp blood glucose levels at 120 mg.dl−1. All infused solutions were 1025 
prepared in a 4.5 % 2H2O-saline solution. Blood glucose was monitored (AccuCheck; Roche 1026 
Diagnostics, Indianapolis, IN) every 10 minutes and donor erythrocytes were infused to maintain 1027 
hematocrit levels during the study. Three arterial blood samples (~100 μl each) were obtained during 1028 
the clamp steady-state period, 90 min after metformin infusion was initiated for determination of 1029 
glucose fluxes as well as arterial glucose, insulin and/or metformin levels. Plasma was stored at −20°C 1030 
until analysis.  Mice were rapidly euthanized through cervical dislocation immediately after the final 1031 
steady-state sample. Tissues were rapidly dissected (within 30 s), freeze-clamped in liquid nitrogen 1032 
and stored at -80°C until further analysis. 1033 
 1034 
Preparation of glucose derivatives for GC-MS analysis. Plasma samples were separated into three 1035 
aliquots. Each aliquot was derivatized separately to obtain di-O-isopropylidene propionate, aldonitrile 1036 
pentapropionate, and methyloxime pentapropionate derivatives of glucose as previously described12,13. 1037 
 1038 
GC-MS analysis. GC-MS analysis employed an Agilent 7890A gas chromatography system with an 1039 
HP-5ms capillary column (Agilent J&W Scientific) interfaced with an Agilent 5975C mass 1040 
spectrometer and was executed as previously described12 with minor modifications. Injection volumes 1041 
were 1 μl with purge flow times between 20 and 120 s. A custom MATLAB function was used to 1042 
integrate each derivative peak in order to obtain mass isotopomer distributions (MIDs) for the 1043 
following ion ranges: aldonitrile, m/z 173–178, 259–264, 284–289, and 370–375; methyloxime, m/z 1044 
145–149; di-O-isopropylidene, m/z 301–308.  MIDs of each fragment were averages of two injections 1045 
per sample. Root mean square error was determined to provide uncertainty and was calculated by 1046 
comparing the MIDs of unlabeled glucose samples to the theoretical MIDs obtained from the known 1047 
abundances of naturally occurring isotopes. 1048 
 1049 
Glucose positional deuterium enrichment analysis. The positional deuterium enrichment at each 1050 
carbon of glucose was determined by least-squares regression as previously described13 using the six 1051 
glucose fragments, all glucose isotopomers up to M+2, and INCA software14 (available at 1052 
http://mfa.vueinnovations.com/mfa). Goodness of fit was assessed by a chi-square test and confidence 1053 
intervals of 95 % were determined as previously described12,15. Fits were accepted according to a chi-1054 
square test (P = 0.05) with nine degrees of freedom.   1055 
 1056 
Glucose Kinetics. The infusion rate of [6,6-2H2]glucose and model-derived, plasma [6,6-2H2]glucose 1057 
enrichment were used to determine glucose turnover (Rt). Assuming steady state conditions, glucose 1058 
disappearance (Rd; mg.kg−1.min−1) is equivalent to Rt. Endogenous glucose production (EndoRa; 1059 
mg.kg−1.min−1) was calculated by subtracting the glucose infusion rate (GIR) from total Rt. The 1060 
model-derived positional deuterium enrichment at carbon 5 (D5) and carbon 2 (D2) of plasma glucose 1061 
allowed the fractional contribution of gluconeogenesis and glycogenolysis to be determined as 1062 
previously outlined16,17. Briefly, fractional contribution of gluconeogenesis (GNG) was obtained by the 1063 
ratio between D5 and D2 (GNG=D5/D2). Fractional contribution of glycogenolysis (GYG) to EndoRa 1064 
was determined from the equation, GYG = 1-GNG. Multiplying by EndoRa allowed for absolute rates 1065 
of glycogenolysis and gluconeogenesis to be calculated. Glucose flux rates for the three clamp steady-1066 
state samples were averaged to obtain representative values for each mouse. 1067 
 1068 
[11C]-Metformin MicroPET. [11C]-Metformin was synthesized by methylation of 1-methylbiguanide 1069 
with [11C] methyl triflate18 and prepared as a solution (0.1-0.5 µg/ml) in 100 mM (NH4)2HPO4, pH 5. 1070 
Animals were anesthetized in a chamber filled with 5 % isoflurane in a mixture of O2 (0.4 L.min-1) and 1071 
air (1.5 L.min-1). After induction of anesthesia, the head of the animal was placed in an acrylic glass 1072 
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holder and anesthesia maintained with isoflurane (1.8–2.0 %) in O2 (0.4 L.min-1) and air (1.5 L.min-1). 1073 
A single bolus of [11C]-metformin (4.6 ± 0.3 MBq/mouse) was injected via a catheter inserted into the 1074 
tail vein, followed by 60 min dynamic PET- and 15 min MR-imaging in a Mediso nanoScan PET/MR 1075 
(Mediso Ltd, Hungary). Respiratory frequency was monitored and body temperature maintained at 36-1076 
37oC. Animals were euthanized at the end of the procedure by cervical dislocation. Data obtained from 1077 
the dynamic PET was reconstructed with a 3D OSEM algorithm (Tera-Tomo 3D, full detector model 1078 
and normal regularization; Mediso Ltd, Hungary) with four iterations and six subsets, voxel size 1079 
0.4×0.4×0.4 mm3. Corrections were made for randoms, dead-time and decay using a delayed 1080 
coincidence window. Attenuation and scatter was not corrected. The 60 min dynamic PET-scans were 1081 
reconstructed as 30 frames increasing in duration from 5 s to 10 min. Multiple regions of interest 1082 
(ROIs) were placed on coronal slices in the organ of interest using PMOD version 3.6 (PMOD 1083 
Technologies Ltd, Zurich, Switzerland) creating a volume of interest (VOI). An image-derived input 1084 
function was generated by averaging images from the first 20 s and placing a circle with a diameter of 1085 
15 pixels on the six slices with the highest activity in the heart (68 µl), representing primarily the 1086 
blood-pool in left ventricle. Hepatic VOIs were drawn in the anterior part of the liver on PET-images 1087 
averaged from 0-60 min in which it can be easily identified. Positioning of all VOIs was controlled in 1088 
each time frame. MR-images were used for defining size and demarcation of liver and left ventricle. 1089 
Time-activity curves were generated from the VOIs. Results are expressed as tissue-to-blood ratio by 1090 
dividing the tissue concentration of [11C]-metformin by the blood concentration at each time point for 1091 
each animal. Area under the curve (AUC) of the tissue-to-blood ratio is a reflection of the tissue 1092 
extraction ratio and represents the distributional relationship between uptake and elimination from the 1093 
tissue of interest. 1094 
 1095 
RT-PCR. RNA was extracted from powdered livers using Trizol reagent and silica columns 1096 
(ThermoFisher #12183-555) using the standard protocol with the exception that Trizol homogenates 1097 
were centrifuged at 12,000 g for 10 min at 4ºC prior to phase separation and the RNA fraction was 1098 
loaded onto silica columns in 25 % (v/v) ethanol to prevent co-precipitation of RNA with glycogen. 1099 
RNA integrity was monitored by electrophoresis. Samples were denatured in 1100 
formamide/formaldehyde loading buffer (Sigma R1386) containing 0.1 % (v/v) SYBR® Safe and 1101 
separated on 1 % (w/v) agarose gels in TAE. cDNA was synthesized using random hexamers and 1102 
oligo(dT) primers using iScript cDNA synthesis kit (Bio-Rad #1725038). RT-PCR was performed 1103 
using SYBR green detection on a Roche LightCycler 480 II. Reactions contained 50 ng template, 0.5 1104 
µM primers and 1×LightCycler 1536 DNA Green master reagent (Roche #05573092001) and 1105 
amplification was performed using a hot-start, touchdown protocol: 95ºC, 7 min followed by 35 cycles 1106 
of 95ºC for 10s, 63ºC > 58ºC (0.5ºC/cycle) for 10s and 72ºC for 10s. Specificity was determined by 1107 
melting curves and agarose gel electrophoresis of reaction products. Relative quantification of target 1108 
genes and propagation of error was determined using 18S as a reference gene and the ΔΔCt method of 1109 
Livak19. Statistical significance of relative expression ratios was tested using REST© 2009 1110 
(http://www.gene-quantification.com/rest-2009.html). 1111 
 1112 
Tissue Metabolites. To avoid even transient hypoxia which results in severe disturbances in tissue 1113 
metabolites20, mice were anaesthetized using isoflurane, the abdomen was exposed and the left lobe of 1114 
the liver was freeze-clamped in-situ using liquid nitrogen cooled Wollenberger tongs. Prior to 1115 
analysis, powdered livers were stored in cryovials in vapour phase liquid nitrogen. Glycogen was 1116 
assayed by a modification of the method of Keppler and Decker21. Briefly, samples were digested with 1117 
10 volumes 1 M KOH at 80ºC for 20 min, adjusted to pH 4.8 with 0.5 volumes 4 N acetic acid and 1118 
incubated with 5 U/ml amyloglucosidase for 2 h at 40ºC. Samples were clarified at 16,000 g for 10 1119 
min and free glucose assayed in reactions containing 50 mM tris-HCl pH 8.1, 1 mM MgCl2, 0.1 % 1120 
(w/v) BSA, 0.5 mM ATP, 0.5 mM NADP+, 0.5 mM iodonitrotetrazolium chloride (INT), 10 μM 1-1121 
methoxy-5-methylphenazinium methyl sulfate, 0.5 U/ml hexokinase and 0.1 U/ml glucose-6-1122 
phosphate dehydrogenase by following the increase in A495. Glucose in perchloric acid extracts was 1123 
assayed as described above but omitting coupling to INT, which forms an insoluble perchlorate 1124 
precipitate. Adenine and Z nucleotides were assayed by ion-pair, reverse phase chromatography on an 1125 
Ultimate 3000-RS HPLC essentially as described by Ryll22. Powdered liver was homogenized in 6 1126 
volumes ice-cold 0.6 N perchloric acid, 0.5 mM EGTA and centrifuged at 16,000 g for 3 min at 4ºC. 1127 
26 
 
Protein pellets were dissolved in 10 volumes 0.5 M NaOH and [protein] determined using Bradford 1128 
reagent. Perchloric acid was extracted from the supernatant by shaking with two volumes 1:3 1129 
trioctylamine:chloroform (~0.6 N trioctylamine) and centrifugation at 2000 g for 1 min at 4ºC to 1130 
induce phase separation. The upper aqueous phase was recovered and neutralized by the addition of 5 1131 
mM phosphate pH 7. Samples were analyzed immediately by injection (20 µl) on a Supelcosil LC-18 1132 
T 150×4.6 mm, 3 µm C18 column equilibrated with mobile phase (A - 100 mM potassium phosphate 1133 
pH 5.5, 8 mM tetrabutylammonium hydrogen sulfate) at 26ºC. The column was resolved with a 1134 
methanol gradient (B = A:methanol 70:30, pH 6): 0 min – 0 % B, 2 min – 0 % B, 16 min – 40 % B, 17 1135 
min – 100 % B, 23 min – 100 % B, and re-equilibrated with A for 8 min. Peaks were detected at A254. 1136 
Skeletal muscle was powdered in a liquid nitrogen-cooled Bessman pulverizer and homogenized with 1137 
10 volumes 0.6 N PCA, 0.5 mM EGTA using a rotor-stator homogenizer. Samples were clarified at 1138 
16,000 g for 5 min at 4ºC, the supernatant neutralized with two volumes 1:3 trioctylamine:chloroform 1139 
as described above and 10 nM P1,P5-di(adenosine 5') pentaphosphate (A5pA) added to inhibit any 1140 
residual myokinase activity. Samples were analyzed immediately by injection (10 µl) on an Accucore 1141 
100×3.0 mm, 2.6 µm C18 column (Thermo 17126-103030) with a 10×3.0 mm guard column (Thermo 1142 
17126-013005) equilibrated with mobile phase (A - 100 mM potassium phosphate pH 5.5, 5 mM 1143 
tetrabutylammonium hydrogen sulfate) at 0.6 ml.min-1 at 26ºC. The column was resolved with an 1144 
acetonitrile gradient (B = A:acetonitrile 75:25, pH 6): 0 min – 0 % B, 1.5 min – 0 % B, 5 min – 10 % 1145 
B, 9 min – 50 % B, 10 min – 100 % B, 13 min – 100 % B and re-equilibrated with A for 6 min. Peaks 1146 
were detected at A254. Water used for mobile phase preparation was filtered through Empore SBD-XC 1147 
cartridge filters to remove impurities and improve baseline stability. Chromatograms were acquired 1148 
and integrated using Chromeleon v7.1 and calibrated using standards prepared in water and 1149 
standardized at A259 (ε = 15.4 mM-1 in 0.1 M phosphate pH 7). Remaining metabolites were assayed in 1150 
0.6 N perchloric acid, 1 mM EDTA extracts neutralized with 0.25 volumes 2 M KOH, 0.4 M KCl, 0.4 1151 
M imidazole. To prevent excessive loss of pyruvate it was necessary to add 500 U/ml catalase 1152 
immediately upon neutralization to remove H2O2, which forms spontaneously in neutralized perchloric 1153 
acid extracts of blood rich tissues and decarboxylates pyruvate to acetate. Lactate was assayed using a 1154 
modification of the method of Noll23 in reactions containing 0.1 M 2-amino-2-methyl-1-propanol pH 1155 
9.2, 20 mM glutamate, 1.5 mM NAD+, 10 μM 1-methoxy-5-methylphenazinium methyl sulfate, 0.5 1156 
mM WST-1, 20 U/ml lactate dehydrogenase and 5 U/ml glutamate-pyruvate transaminase. A440 was 1157 
recorded and [lactate] determined by interpolation of a standard curve prepared using lithium lactate. 1158 
Pyruvate was assayed as described by Passonneau and Lowry24 in reactions containing 50 mM 1159 
phosphate pH 7, 20 μM NADH and 0.04 U/ml lactate dehydrogenase. The decrease in fluorescence 1160 
(λex = 345 nm, λem = 465 nm) was recorded and calibrated using known quantities of sodium pyruvate. 1161 
G6P, F6P and F-1,6-P2 were assayed using a modification of the method of Racker25 in reactions 1162 
containing 50 mM tris-HCl pH 8.5, 5 mM MgCl2, 0.1 mM EDTA, 100 μM NADP+, 0.2 U/ml 1163 
diaphorase and 20 μM resazurin. Glucose-6-phosphate dehydrogenase (0.1 U/ml), phosphoglucose 1164 
isomerase (0.2 U/ml) and recombinant spinach chloroplast fructose-1,6-bisphosphatase (1 U/ml, 1165 
prepared in E.coli) were added sequentially and the increase in resorufin fluorescence (λex = 540 nm, 1166 
λem = 590 nm) recorded and calibrated by addition of known quantities of NADH. Fructose-2,6-1167 
bisphosphate was assayed using PPi-dependent fructose-6-phosphate 1-phosphotransferase from potato 1168 
exactly as described by Van Schaftingen26. 3’,5’-cAMP was assayed in trichloroacetic acid (TCA) 1169 
extracts using a commercial enzyme immunoassay from Sigma (CA-201). Briefly, powdered tissue 1170 
was homogenized in 10 volumes ice-cold 5 % (w/v) TCA and centrifuged at 16,000 g for 10 min at 1171 
4ºC. The supernatant was extracted 4× 3 volumes water-saturated diethyl ether, frozen and lyophilized 1172 
in a Speedvac. Samples were reconstituted in the supplied assay buffer and analyzed according to the 1173 
manufacturer’s instructions. 1174 
 1175 
Enzyme assays. GCK (EC 2.7.1.2) activity was assayed in cytosolic fractions (which substantially 1176 
improves the assay by removing G6PC) prepared using the recommendations of Davidson27 in 1177 
reactions containing 50 mM HEPES pH 7.4, 0.1 M KCl, 0.1 mM EDTA, 7.5 mM ATP, 0.5/100 mM 1178 
glucose, 0.5 mM NAD+, 2.5 mM DTT, 1 % (w/v) BSA, 2 U/ml glucose-6-phosphate dehydrogenase 1179 
and 10 µM rotenone at 30ºC. Activity at 0.5 mM glucose was subtracted from that at 100 mM glucose 1180 
to correct for hexokinase-1 activity. Blanks were performed in the absence of glucose and/or ATP. 6-1181 
phosphofructo-1-kinase (EC 2.7.1.11) activity was determined by the method of Castano28. Extracts 1182 
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(40 µg) were incubated in 50 mM HEPES pH 7.1, 0.1 M KCl, 6.5 mM MgCl2, 1.5 mM ATP, 0.25 mM 1183 
fructose-6-phosphate, 0.75 mM glucose-6-phosphate, 0.1 mM AMP, 5 mM Pi, 1 mM NH4Cl, 0.2 mM 1184 
NADH, 0.05 % (w/v) BSA, 2 mM 2-mercaptoethanol, 10 µM rotenone, 1 U/ml aldolase, 10 U/ml 1185 
triosephosphate isomerase, 2 U/ml glycerol-3-phosphate dehydrogenase and 1 U/ml phosphoglucose 1186 
isomerase at 30ºC. Coupling enzymes were buffer exchanged over Sephadex G-25 equilibrated with 1187 
10 mM tris-HCl pH 7.1 to remove sulfate. Total PK (EC 2.7.1.40) activity and ratio at 1.3/6.6 mM 1188 
phosphoenolpyruvate at 66 mM KCl was determined as described by Blair29. Lysates (10 µg) were 1189 
incubated in reactions containing 100 mM tris-HCl pH 7.5, 66 mM KCl, 10 mM MgSO4, 2.5 mM 1190 
ADP, 0.2 mM NADH, 10 µM rotenone, 1 µM microcystin-LR, 0.05 % (w/v) BSA, 3.2 U/ml lactate 1191 
dehydrogenase and 1.3 or 6.6 mM phosphoenolpyruvate. PEPCK-C (EC 4.1.1.32) was assayed using 1192 
the method of Petrescu30. Cytosolic extracts (100 µg) were incubated in reactions containing 50 mM 1193 
tris-HCl pH 7.4, 1 mM MnCl2, 0.1 mM EGTA, 0.05 % (w/v) BSA, 0.5 mM PEP, 0.2 mM NADH, 10 1194 
µM rotenone, 0.2 mM 2-deoxy-GDP, 2 U/ml malate dehydrogenase and either 20 mM NaCl or 20 mM 1195 
NaHCO3 (saturated with CO2) at 30ºC. FBP1 (EC 3.1.3.11) activity was assayed as described above. 1196 
AMPD1 (EC 3.5.4.6) was assayed in reactions containing 50 mM MOPS pH 7.2, 100 mM KCl, 1 mM 1197 
DTT, 0.05 % (w/v) BSA, 1 mM ATP, 0.2 mM AMP, 7.5 mM 2-oxoglutarate, 0.15 mM NADH and 5 1198 
U/ml glutamate dehydrogenase. All assays were performed in a final volume of 200 µl and monitored 1199 
by changes in A340. Initial rates were determined from the linear phase and activity calculated 1200 
assuming εNAD(P)H = 6.22 mM-1.cm-1. G6PC (EC 3.1.3.9) activity was determined by monitoring the 1201 
release of Pi using the compleximetric method of Saheki31. Extracts (20 µg) were incubated in 20 mM 1202 
MOPS pH 7.2, 100 mM NaCl, 2 mM 2-mercaptoethanol containing 10 mM glucose-6-phosphate or 1203 
glycerol-2-phosphate (to correct for background due to non-specific phosphatases) for 20 min at 30ºC. 1204 
Reactions were quenched by the addition of 1 % (w/v) SDS and an aliquot (25 µl) was removed for 1205 
determination of released phosphate by sequential addition of 180 µl 15 mM zinc acetate, 100 mM 1206 
ammonium molybdate and 45 µl 10 % (w/v) ascorbic acid (adjusted to pH 5 with 10 N NaOH). 1207 
Reactions were left to develop for 15 min at 30ºC and A850 recorded. Pi was calculated by interpolation 1208 
of a standard curve prepared using desiccated KH2PO4. CS (EC 2.3.3.1) was assayed using the method 1209 
of Srere32. Lysates (10 µg) were incubated in reactions containing 50 mM tris-HCl pH 8.1, 0.1 mM 1210 
EDTA, 0.1 mM 5’5-dithiobis(2-nitrobenzoic acid) (DTNB), 0.3 mM acetyl-CoA and 0.5 mM 1211 
oxaloacetate at 30ºC. Blanks were performed in the absence of oxaloacetate. A412 was monitored and 1212 
activity calculated from the linear phase assuming εTNB2- = 14.15 mM-1.cm-1. PC (EC 6.4.1.1) was 1213 
assayed by coupling the formation of oxaloacetate to the reduction of DTNB using CS. Lysates (20 1214 
µg) were incubated in reactions containing 50 mM tris-HCl, 50 mM NaHCO3, 5 mM MgCl2, 2.5 mM 1215 
ATP, 0.1 mM acetyl-CoA, 0.2 mM DTNB, 5 mM pyruvate and 5 U/ml citrate synthase at 30ºC. 1216 
Blanks were performed in the absence of pyruvate and A412 was monitored as described for CS. GS 1217 
(EC 2.4.1.11) was assayed by the method of Thomas33. Lysates (50 µg) were incubated in reactions 1218 
containing 25 mM tris-HCl pH 7.8, 50 mM NaF, 1 mM EDTA, 0.9 % (w/v) glycogen, 1 mM DTT, 20 1219 
µM 1-deoxynojirimycin, 4.4 mM [U-14C] UDP-glucose (0.1-0.2 mCi.mmol-1) in the absence and 1220 
presence of 10 mM G6P for 20 min at 30ºC. Reactions were stopped by spotting on squares of 3MM 1221 
filter paper and immersion in ice-cold 66 % (v/v) ethanol. Filters were washed 3×20 min with 66 % 1222 
(v/v) ethanol, rinsed with acetone and [14C] incorporation into glycogen determined by scintillation 1223 
counting in Emulsifier Safe (Perkin Elmer). GPa (EC 2.4.1.1) was assayed in the reverse direction 1224 
using the method of Gilboe34 following the recommendations of Stalmans35. Lysates (50 µg) were 1225 
incubated in reactions containing 50 mM MES pH 6.5, 50 mM [U-14C] glucose-1-phosphate (0.02 1226 
mCi.mmol-1), 150 mM NaF, 5 mM EDTA, 1 % (w/v) glycogen, 20 µM 1-deoxynojirimycin, 15 mM 2-1227 
mercaptoethanol and 0.5 mM caffeine at 30ºC for 20 min. Reactions were spotted on filters and 1228 
processed as described for GS with the exception that room temperature 66 % (v/v) ethanol was used 1229 
for quenching to prevent high blanks caused by the co-precipitation of glucose-1-phosphate. AMPK 1230 
phosphotransferase activity (EC 2.7.11.1) was assayed using immunoprecipitates. Briefly, lysates (50 1231 
µg) were incubated with 2 µg anti-AMPKα1 or anti-AMPKα2 and 5 µl protein G Sepharose for 2 h at 1232 
4ºC. Immune complexes were pelleted at 500 g for 1 min and washed 3× 1 ml lysis buffer and 2× 1 ml 1233 
50 mM tris-HCl pH 8, 0.1 mM EGTA. Phosphotransferase activity was determined in reactions 1234 
containing 50 mM HEPES pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.1 mM [γ-32P] ATP (250 1235 
CPM.pmol-1), 0.1 mM AMARA (NH2-AMARAASAAALARRR-COOH). Reactions were quenched 1236 
by spotting onto P81 filters and immersion in 75 mM phosphoric. Filters were washed 3× 10 min with 1237 
28 
 
75 mM phosphoric acid, rinsed with acetone and [32P] incorporation determined by Cherenkov 1238 
counting. With the exception of AMPK, 1 U = 1 μmol product formed per min at 30ºC. For AMPK, 1 1239 
U = 1 nmol phosphate incorporated per min at 30ºC. 1240 
 1241 
Data Analysis. Fitting to models was performed by least squares non-linear regression using 1242 
Levenberg-Marquardt minimization using Graphpad Prism v5.0. Area under the curve was calculated 1243 
using the trapezoidal rule with subtraction of the area below baseline (t = 0). Statistical significance 1244 
was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05. All data were 1245 
normally distributed based on D'Agostino-Pearson omnibus tests and sample variance was similar 1246 
between groups being compared. 1247 
 1248 
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Figure S1. (a) Metformin inhibition curves of purified mouse FBP1 and rabbit muscle AMPD1 activity. Assays were performed as 
described in methods and results are expressed as the ratio of the maximum activity in the absence of compound (V/Vo). (b) Multiple 
sequence alignment of FBPase enzymes from different species (black = conserved, white = not conserved). Residues contributing to AMP 
binding are highlighted in yellow and stars represent residues mutated in this study. Numbering of mouse FBP1 is shown on the top line. 
Mm = M. musculus, Hs = H. sapiens, Ss = S. scrofa, Dm = D. melanogaster, Dr = D. rerio and Sc = S. cerevisiae. (c) Recombinant FBP1 
WT or G27P were mixed with unmodified or 2’/3’-EDA-AMP-agarose (AMP-agarose) in the presence or absence of 0.5 mM free AMP. 
After washing, bound proteins were eluted and assessed by SDS-PAGE with Coomassie staining. Results are representative of three 
independent experiments. (d) Thermal stability curves of recombinant FBP1 WT and G27P in 20 mM HEPES pH 7.4, 100 mM KCl and 
1 mM MgCl2 (HBK) in the presence of the indicated ligands. Thermomelt curves are representative of a single experiment and Tm values 
represent mean ± SD of three independent experiments. 
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Figure S2. (a) Western blot analysis of FBP1 expression in a panel of mouse tissues (C57BL/6NTac). Equal amounts of protein (20 µg) 
were loaded for each tissue. Islets of Langerhans were isolated from pancreas by intraductal collagenase digestion and hand picking under 
a stereomicroscope. Arrows indicate the position of FBP1 and a band of unknown identity (non-specific). TA = Tibialis anterior. (b) Western 
blot analysis of FBP1 expression in liver, kidney, ileum and testes from FBP1WT/WT (WT) and FBP1G27P/G27P (KI) mice. Representative results 
from three mice are shown. (c) FBPase activity in liver, kidney, ileum and testes homogenates from WT and KI mice. n = 5. 
*P < 0.05 (WT vs. KI). Statistical significance was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05.  
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Figure S3. FBP1WT/WT (WT) or FBP1G27P/G27P (KI) mice were housed in metabolic phenotyping cages and after a 3 h acclimatization 
period, food intake (a, b) respiratory exchange ratio (RER) (c, d) and ambulatory activity (e, f) were monitored for a period of 21 h. For 
each parameter a line graph depicting the trend over the full 21 h period and bar graphs of the mean values observed during the day and 
night phase are shown. Results represent mean ± SE, n = 10. *P < 0.05 (Day vs. night). Statistical significance was determined using 
unpaired, two-tailed Student’s t-test and an alpha level of 0.05. 
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Figure S4. (a-o) Quantitative Western blot analysis of pS240/244 S6 (a), G6PC (b), GLUT2 (c), GCK (d), GCKR (e), HXK1 (f), PFKL (g), 
FBP1 (h), pS33 PFKFB1 (i), PEPCK-C (j), PEPCK-M (k), pS8 GYS2 (l), pS641 GYS2 (m), pS15 PYGL (n) and OCT1 (o) in liver 
homogenates from mice fasted overnight for 16 h (Fasted) or subsequently given free access to standard chow for 4 h (Refed). 
n = 5 FBP1WT/WT (WT) and 7 FBP1G27P/G27P (KI) per group with the exception of (o) where n = 3 for all groups. *P < 0.05 (Fasted vs. refed).  
Statistical significance was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05.
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Figure S5. (a-i) Glucokinase (GCK) (a), glucose-6-phosphatase (G6PC) (b), phosphofructokinase-1 (PFK1) (c), pyruvate kinase (PK) (d), 
PK (1.3/6.6 mM PEP ratio) (e), pyruvate carboxylase (PC) (f), citrate synthase (CS) (g), glycogen synthase (GS ± 10 mM G6P ratio) (h) 
and glycogen phosphorylase (GPa) (i) activity in liver homogenates from overnight fasted (16 h) or refed (4 h) FBP1WT/WT (WT) or 
FBP1G27P/G27P (KI) mice. (j-o) Expression of Pck1 (j), Pparg1c (k), Foxo1a (l), Fasn (m), G6pc (n) and Gck (o) mRNA in liver from overnight 
fasted (16 h) or refed (4 h) FBP1WT/WT (WT) or FBP1G27P/G27P (KI) mice determined by qPCR. Results represent mean ± SE, n = 5 (WT) and 
7 (KI) per group. *P < 0.05. Statistical significance was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05. 
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Figure S6. Effects of AICAR administration on skeletal muscle biochemistry. (a-g) Vehicle (0.9 % saline) or AICAR (250 mg.kg-1  i.p.) 
was administered to fasted (16 h) mice and after 60 min exposure, gastrocnemius (GAS) muscle biopsies were taken and assayed for (a-f) 
AMPK activation and downstream signaling by Western blotting and (g) levels of adenine and Z-nucleotides. (a) The blot image depicts 
three representative mice from each treatment group. Quantitative analysis of pT172 AMPKα (b), pS212 ACC2 (d), pS237 TBC1D1 and 
pS792 RAPTOR (e, f) from the entire sample set was also performed. Results are expressed as phosphoprotein/total protein ratio normalized 
to the WT-vehicle group. (c) AMPK activation was also assessed by a radiometric immunoprecipitation kinase assay of AMPKα2 complexes. 
Results represent mean ± SE, n = 3-5 per treatment group. *P < 0.05 (Vehicle vs. AICAR). #P < 0.05 (WT vs. KI). Statistical significance
was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05. 
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Figure S7. Schematic to illustrate the protocol followed when performing metformin tolerance tests (a) and metformin-euglycemic clamps (b). 
Arterial blood glucose (c) and glucose infusion rate (d) during metformin-euglycemic clamps in FBP1WT/WT (WT) or FBP1G27P/G27P (KI). Mice 
were fasted for 5 h and infused i.v. with metformin (1.875 mg.kg-1.min-1) and a variable infusion of 50 % glucose to maintain euglycemia at 120 
mg.dl-1 over a period of 120 min. (e) Plasma and liver metformin concentrations at the end of the clamp period. Results represent mean ± SE, 
n = 4 (WT) and 6 (KI). (f-m) Additional analysis of tissue biopsies from WT and KI mice infused with the higher dose of metformin (3.75 
mg.kg-1.min-1 i.v.) during a euglycemic clamp as described in Fig. 5. Plasma insulin levels at the beginning (Resting) and end of the clamp protocol 
(Clamp). (g) GAS muscle concentration of metformin at the end of the clamp protocol corrected for blood contamination. (h) GS activity ratio 
(± 10 mM G6P), (i-j) quantification of pS8 and pS641 GYS2 phosphorylation, (k) GPa activity, (l) quantification of pS15 PYGL phosphorylation   
and (m) glycogen content in liver biopsies. Results represent mean ± SE, n = 8 (WT-resting), 9 (WT-clamp), 10 (KI-resting) and 10-11 (KI-clamp).
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Figure S8. Metformin pharmacokinetics determined by [11C]-metformin positron emission tomography (PET). Anaesthetized 
FBP1WT/WT (WT) or FBP1G27P/G27P (KI) were administered a single bolus injection of [11C]-metformin via tail vein injection and dynamic 
whole-body PET acquired for a period of 60 min. (a) Representative coronal PET images merged with a 15 min T1-weighted Magnetic 
resonance imaging (MRI) scan. (b, c) Liver/heart activity ratios plotted against time (b) and the corresponding AUC (c) for WT and KI mice. 
Results represent mean ± SE, n = 5. 
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Figure S9. (a-b) Additional analysis of liver biopsies from diabetic mice (high-fat diet model) administered with vehicle (water) or 
metformin (250 mg.kg-1 p.o.)  for 2 h as described in Fig. 6i-k. Quantitative Western blotting of pS33 PFKFB1 (a) and pS133 CREB 
(b). Results are expressed as phosphoprotein/total protein ratio normalized to the WT-vehicle group. 
n = 6 (WT-vehicle), 6 (WT-metformin), 5-6 (KI-vehicle) and 5-6 (KI-metformin). *P < 0.05 (Vehicle vs. metformin). 
Statistical significance was determined using unpaired, two-tailed Student’s t-test and an alpha level of 0.05. 
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Parameter FBP1 FBP1 G27P
Specific activity (U.mg-1) 34.1 ± 2.5 32.1 ± 3.58
Ratio (pH 7.2/9.4) 2.75 ± 0.11 2.72 ± 0.15
Km (F-1,6-P2) µM 2.92 ± 0.49 2.86 ± 0.16
Ka (Mg2+) mM 0.36 ± 0.02 0.37± 0.04
h (Mg2+) 1.86 ± 0.04 1.86 ± 0.19
IC50 (AMP) µM 13.4 ± 0.35 4520 ± 291
h (AMP) 1.70 ± 0.09 1.77 ± 0.15
Kd (TNP-AMP) µM 19.4 ± 1.86 >100
IC50 (F-2,6-P2) µM 1.69 ± 0.09 1.52 ± 0.08
h (F-2,6-P2) 1.4 ± 0.15 1.45 ± 0.14
IC50 (ZMP) µM 108 ± 13 >10,000
h (ZMP) 1.56 ± 0.1 ND
IC50 (IMP) µM 4530 ± 76 4620 ± 37.5
h (IMP) 1.71 ± 0.03 1.72 ± 0.04
IC50 (FBPase-1 inhibitor*) µM 4.58 ± 0.16 > 100
IC50 (MB05032**) µM 0.3 ± 0.03 ~ 500***
* 5-chloro-2-(N-(2,5-dichlorobenzenesulfonamido))-benzoxazole (CAS 883973-99-7)
** 2-amino-5-isobutyl-4-[5-phosphono-2-furanyl]thiazole (CAS 261365-11-1)
*** Estimated value from partial curves due to limits of compound solubility
Supplementary Table 1. Table summarizing the kinetic properties of WT mouse FBP1 and the AMP-insensitive mutant G27P (6HIS tag 
removed by HRV-3C protease). Results represent the mean ± SD of at least three independent experiments. 
Supplementary Table 2. FBP1WT/WT (WT) or FBP1G27P/G27P (KI) mice were fasted overnight for 16 h (Fasted) or subsequently given free 
access to standard chow for 4 h (Refed). Selected metabolites from fasted and refed mouse livers are summarized. Results are expressed 
as mean ± SE, n = 5 (WT) and 7 (KI) per group. *P < 0.05 (Fasted vs. refed).
Lactate 2.68 ± 0.12 12.0 ± 0.6 2.72 ± 0.05 11.9 ± 0.6
Pyruvate 0.14 ± 0.01 0.66 ± 0.05 0.15 ± 0.01 0.67 ± 0.05
Glucose 15.5 ± 0.4 25.4 ± 1.6 14.2 ± 0.8 24.9 ± 1.0
G6P 0.41 ± 0.05 0.88 ± 0.1 0.43 ± 0.1 0.87 ± 0.07
F6P 0.11 ± 0.01 0.24 ± 0.03 0.11 ± 0.02 0.23 ± 0.02
0.014 ± 0.002 0.044 ± 0.01 0.013 ± 0.002 0.051 ± 0.008
0.0019 ± 0.0003 0.0027 ± 0.0005 0.0018 ± 0.0002 0.0025 ± 0.0004
Fasted
µmol.g protein-1
Refed
µmol.g protein-1
Fasted
µmol.g protein-1
Refed
µmol.g protein-1
FBP1WT/WT FBP1G27P/G27P 
F-1,6-P2
F-2,6-P2
*
*
*
*
*
*
*
*
*
*
*
*
Supplementary Table 3. FBP1WT/WT (WT) or FBP1G27P/G27P (KI) mice were fasted overnight for 16 h (Fasted) or subsequently given 
free access to standard chow for 4 h (Refed). Adenine nucleotides from fasted and refed mouse livers are summarized. Results are 
expressed as mean ± SE, n = 5 (WT) and 7 (KI) per group. Adenylate energy charge was calculated as defined by Atkinson 
(ATP + ½ADP)/(ATP + ADP + AMP). *P < 0.05 (Fasted vs. refed).
WT (Fasted) 1.36 ± 0.04 7.58 ± 0.24 22.93 ± 0.33 0.060 ± 0.002 0.838 ± 0.003
WT (Refed) 1.58 ± 0.07 7.94 ± 0.16 22.31 ± 1.01 0.072 ± 0.005 0.825 ± 0.008
KI (Fasted) 1.42 ± 0.06 7.65 ± 0.31 23.31 ± 0.28 0.061 ± 0.003 0.838 ± 0.006
KI (Refed) 1.53 ± 0.02 7.71 ± 0.16 22.70 ± 0.76 0.068 ± 0.003 0.831 ± 0.004
AMP
µmol.g protein-1
ADP
µmol.g protein-1
ATP
µmol.g protein-1 AMP/ATP 
Energy
Charge
* *
Supplementary Table 4. Vehicle (0.9 % saline) or AICAR (250 mg.kg-1 i.p.) was administered to fasted (16 h) FBP1WT/WT (WT) 
or FBP1G27P/G27P (KI) mice and after 60 min exposure, liver biopsies were taken and assayed for adenine and Z-nucleotides 
levels. Results represent mean ± SE, n = 5 per treatment group. *P < 0.05 (Vehicle vs. AICAR). #P < 0.05 (WT vs. KI).
FBP1WT/WT FBP1G27P/G27P 
Vehicle 
μmol.g protein-1 
AICAR 
μmol.g protein-1 
Vehicle 
μmol.g protein-1 
AICAR 
μmol.g protein-1 
AMP 1.31 ± 0.08 1.00 ± 0.04 1.28 ± 0.10 1.68 ± 0.17 
ADP 7.61 ± 0.34 2.83 ± 0.04 7.64 ± 0.18 6.27 ± 0.60 
ATP 20.0 ± 0.46 16.5 ± 0.12 19.8 ± 0.26 18.8 ± 0.82 
AMP:ATP 0.07 ± 0.01 0.06 ± 0.00 0.07 ± 0.01 0.10 ± 0.01 
Energy Charge 0.82 ± 0.01 0.88 ± 0.00 0.82 ± 0.00 0.82 ± 0.00 
NAD+ 6.24 ± 0.28 7.62 ± 0.27 6.67 ± 0.20 7.73 ± 0.34 
ZMP N.D. 40.9 ± 1.9 N.D. 34.8 ± 2.96 
ZDP Not resolved Not resolved Not resolved Not resolved 
ZTP N.D. 8.57 ± 0.11 N.D. 10.6 ± 0.65 
ZMP:ATP / 2.48 ± 0.12 / 1.98 + 0.21 
* * #
* * #
* #
*#
* *
* #
#
#
TAN** 28.9 ± 0.38 20.3 ± 0.13 28.7 ± 0.33 26.8 ± 1.54 * #
**TAN = total adenine nucleotides (AMP+ADP+ATP)
Supplementary Table 5. FBP1WT/WT (WT) and FBP1G27P/G27P (KI) mice were fasted for 16 h and dosed with vehicle (water) 
or metformin (250 mg.kg-1 p.o.). After 1 h exposure, blood and liver biopsies were taken and assayed for adenine nucleotides.
*P < 0.05 (Vehicle vs. metformin).
WT (vehicle) 1.27 ± 0.02 6.93 ± 0.57 23.13 ± 1.19 0.056 ± 0.003 0.848 ± 0.009
WT (metformin) 2.36 ± 0.12 10.23 ± 0.36 21.52 ± 0.55 0.109 ± 0.003 0.781 ± 0.004
KI (vehicle) 1.23 ± 0.08 7.22 ± 0.49 24.24 ± 0.95 0.051 ± 0.003 0.852 ± 0.007
KI (metformin) 2.63 ± 0.3 11.54 ± 0.64 20.09 ± 0.9 0.132 ± 0.016 0.755 ± 0.014
AMP
µmol.g protein-1
ADP
µmol.g protein-1
ATP
µmol.g protein-1 AMP/ATP 
Energy
Charge
* * *
* * *
*
**
Supplementary Table 6. After 12 weeks of dietary intervention FBP1WT/WT (WT) and FBP1G27P/G27P (KI) mice were fasted for 16 h, 
administered vehicle (water) or metformin (250 mg.kg-1 p.o.) and liver biopsies were taken after 2 h of drug treatment for adenine 
nucleotides. *P < 0.05 (Vehicle vs. metformin).  
WT (vehicle) 1.23 ± 0.14 7.00 ± 0.29 22.64 ± 0.73 0.055 ± 0.007 0.847 ± 0.07
WT (metformin) 2.29 ± 0.36 9.87 ± 0.75 19.23 ± 0.73 0.123 ± 0.028 0.763 ± 0.017
KI (vehicle) 1.20 ± 0.12 6.87 ± 0.38 22.46 ± 1.12 0.055 ± 0.007 0.847 ± 0.011
KI (metformin) 2.00 ± 0.25 9.70 ± 0.34 19.87 ± 0.47 0.105 ± 0.013 0.777 ± 0.008
AMP
µmol.g protein-1
ADP
µmol.g protein-1
ATP
µmol.g protein-1
Energy
ChargeAMP/ATP 
* * * *
* * * *
*
*
Supplementary Table 7. After 12 weeks of dietary intervention FBP1WT/WT (WT) and FBP1G27P/G27P (KI) mice were fasted for 16 h, 
administered vehicle (water) or metformin (250 mg.kg-1 p.o.) and liver biopsies were taken after 2 h of drug treatment for metabolites.
*P < 0.05 (Vehicle vs. metformin). #P < 0.05 (WT vs KI).  
Glucose 28.7 ± 1.1 20.7 ± 1.3 28.1 ± 1.1 24.6 ± 1.5
G6P 0.46 ± 0.02 0.40 ± 0.01 0.47 ± 0.06 0.47 ± 0.02
F6P 0.15 ± 0.01 0.11 ± 0.01 0.15 ± 0.02 0.15 ± 0.01
0.013 ± 0.005 0.025 ± 0.007 0.012 ± 0.003 0.016 ± 0.004
Vehicle
µmol.g protein-1
Metformin
µmol.g protein-1
Vehicle
µmol.g protein-1
Metformin
µmol.g protein-1
FBP1WT/WT FBP1G27P/G27P 
F-1,6-P2
*
#
#
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